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Introduction
Summary
Macrophages (Mph) are major effector cells of the innate immune system. 
Mph are broadly divided into two types: pro-inflammatory Mph1 and anti-
inflammatory Mph2. A distinctive feature described between human Mph1 and 
Mph2 is the high reactive oxygen species (ROS) production by Mph1, whereas 
Mph2 are being described as a non-ROS producing cell. ROS generated by 
Mph are usually associated with oxidative stress. However, ROS produced in 
the immunological synapse or produced in lower amounts can inhibit T cell 
activation. In addition, ROS serve as second messenger in various signaling 
pathways by changing specific proteins. These redox changes are in many cases 
associated with altered activity and effects on signaling pathways or cellular 
processes. ROS are thus being produced as a result of normal cell physiology or 
due to ageing or stress, but can also be produced in the context of immunological 
defense by a specific enzymatic system. A naturally occurring polymorphism 
in the NADPH oxidase complex member Ncf1 was found to regulate the
severity of arthritis in rats. This polymorphism caused reduced ROS production 
and promoted the activation of arthritogenic T cells. The main producers of 
phagocytic NADPH oxidase (NOX2)-derived ROS are neutrophils and Mph. It 
was shown using transgenic mice expressing a functional NOX2 restricted to 
Mph that Mph could inhibit T cell responses in a ROS-dependent fashion. Thus 
NOX2-derived ROS are involved in immune modulation and cellular signaling 
as well. The scope of this thesis was to obtain more insight in the role of ROS 
being produced by the human M-CSF-differentiated anti-inflammatory Mph2 
in immune modulation.
Macrophage differentiation
In the bone marrow, hematopoietic progenitor cells give rise to neutrophils 
and cells from the mononuclear phagocyte system, including circulating blood 
monocytes (Mn), tissue macrophages (Mph) and dendritic cells (Figure 1) 
(1,2). Mn are released into the circulation upon maturation where they remain 
for a few days before migrating into all the tissue compartments in the body. 
There the Mn will differentiate into resident Mph and by adapting to their local 
environment, Mph such as Kupffer cells (liver), alveolar Mph (lung), and microglia 
(central nervous system) develop. These Mph types are morphologically and 
phenotypically very different, underscribing the plasticity of Mph. Mph are 
major effector cells of the innate immunity; they engulf and kill pathogens, but 
are also involved in tissue repair and resolution of inflammation. Under the 
influence of colony stimulating factors (CSF), including macrophage (M)-CSF 
and granulocyte-macrophage (GM)-SCF, Mn are differentiated from progenitor 
cells. This became evident when observing osteopetrotic mice having a genetic 
defect that makes them M-CSF deficient (3). These mice have severe reductions 
in circulating Mn, and almost complete absence of various myeloid cells 
including osteoclasts and resident peritoneal Mph. The majority of the tissue 
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Mph depend upon signaling through the CSF-1R for their migration, survival 
and (re)population (4).
Since M-CSF is constitutively present in blood, it is thought that an anti-inflam- 
matory Mph phenotype is maintained under homeostatic conditions (5). 
However, under the influence of environmental factors, including signals like 
cytokines, chemokines, and TLR ligands, resident Mph can undergo pheno- 
typic and functional differentiation, thereby resulting in different Mph 
populations (6-8). This was shown in an elegant study by Arnold et al. using in vivo
tracing methods where inflammatory Mph switched to an anti-inflammatory 
Mph phenotype in response to a changed microenvironment (9). 
Macrophage plasticity during inflammation
In response to various inflammatory and immune stimuli, tissue-resident Mph 
undergo local activation. In addition, Mn are recruited causing an accumulation 
of tissue Mph with a pro-inflammatory phenotype (Mph1) contributing to 
inflammation. Mph1 phagocytose debris, invading micro-organisms and 
opsonized particles, thereby triggering a pro-inflammatory response with 
production of pro-inflammatory mediators, including Interleukin (IL)-1β, 
IL-6, IL-12, and tumor necrosis factor-α (TNF)-α (10). During the phagocytosis 
of apoptotic cells, Mph dampen their pro-inflammatory activities, acquiring 
characteristics of anti-inflammatory Mph2; Mph that can initiate tissue healing 
and repair by producing the anti-inflammatory mediators TGF-β, IL-10, and 
prostaglandin E2 (11,12). 
In a model of glomerulonephritis in the kidney, ablation of Mn and Mph 
diminished the amount of tissue injury (13,14). In addition, Kupffer cell depletion 
in a model of liver injury using clodronate liposomes attenuated liver damage 
(15). Mph depletion in a model of autoimmune diabetes blocked disease, and 
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transplantation in the rat (16,17). This implicates that under several conditions 
Mph depletion could be of therapeutic interest. However, eliminating Mph can 
also have disadvantages. It has been demonstrated that hepatic Mph were 
necessary for matrix regression and regulating cell proliferation following liver 
injury (18). Similarly, in muscle Mph are needed to enhance myogenic growth by 
releasing trophic factors (19). These Mph depletion studies confirm in vivo that 
different Mph types exist: depletion does not only affect the pro-inflammatory 
function of Mph but also the wound healing function.
Macrophages in chronic inflammatory diseases
Lately there has been an increasing interest in the role of Mph in chronic 
inflammatory diseases. In atherosclerosis a persistent recruitment of Mn 
into atherosclerotic lesions is observed, where a variety of pro- and anti-
inflammatory Mph can be found (20). A damaging role for Mph1 has been 
indicated in atherosclerosis, whereas Mph2 were shown to be protective (21,22). 
In addition, Mph play also a central role in the pathogenesis of rheumatoid 
arthritis (RA). In steady-state conditions a balance is established that allows 
normal joint function. This balance can shift towards an inflammatory pathway 
by increased production of growth factors that promote Mph1 development 
and increased production of pro-inflammatory cytokines such as TNF-α and 
IL-6 further favouring Mph1 progression (23). Furthermore, in obesity-induced 
inflammation Mph1 are considered to be the major inflammatory cell in adipose 
tissue, whereas normally resident adipose tissue Mph are non-inflammatory 
and regarded as Mph2 (24). 
Macrophage 2-like phenotypes
Resident tissue Mph express the Mph2 marker CD163, indicating an Mph2 
phenotype in vivo (25). Mph2 are also found in the lung where they function to 
protect against unwanted immune responses (26). They were also documented 
in a Th2-mediated inflammatory setting such as nematode infection (27). 
Embryonic Mph and Mph isolated from placentae and tumors also display 
characteristics of Mph2 (28-30). Additionally, coculturing monocytes with Tregs 
differentiated these cells toward Mph2 (31). Tumor-associated Mph (TAMs) also 
have Mph2 properties. TAMs originate from circulating monocytic precursors, 
which are recruited to the tumor in response to secreted chemokines and 
cytokines derived from cancer cells (32). They express high levels of the 
mannose receptor, are poor at presenting antigen and their cytokine profile 
consist of high IL-10 and low IL-12 production (33). The role of TAMs in 
tumors involves tumor progression and metastasis, immune suppression, and 
angiogenesis. Thus functionally different Mph2-like phenotypes have already 
been documented. 
Although the results described above suggest fully polarized functions, 
Mph with overlapping phenotypes have been observed as well. In human 
Mn infected with cytomegalovirus and in adipose tissue Mph a mixed gene 
profile expressing both Mph1 and Mph2 genes was observed (34,35). In 
addition, oxidized phospholipid-treated murine Mph were identified as a new 
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Mph phenotype which is distinctly different from Mph1 and Mph2 (36). Thus 
ample Mph-like phenotypes have been observed, indicating the complexity of 
defining a specific Mph phenotype.
 
Macrophage activation
Interferon-γ (IFN-γ) was the first identified marker that could activate Mph 
(37). Later, LPS and GM-CSF were found to promote the generation of Mph1 
(38). Factors that skew Mph towards Mph2 are M-CSF, IL-4, IL-13, immune 
complexes, Wnt5a, IL-10, or TGF-β, indicating great heterogeneity (39-43). 
These activators all induce a distinct, as well as partially overlapping, pattern of 
gene expression, thus presenting different Mph2 subsets. Mph2 are induced 
by M-CSF, Mph2a are induced by IL-4 or IL-13, Mph2b are induced by exposure 
to immune complexes, agonists of TLRs or IL-1R, and Mph2c are induced by IL-
10 and glucocorticoid hormones (39). Functionally, Mph2a are responsible for 
wound healing and Mph2b together with Mph2c for immune regulation. Th2 
driven inflammation is induced by Mph2b, whereas Mph2c are predominantly 
involved in deactivating immunoregulation (39). Overall, Mph2 participate in Th2 
responses, dampen inflammation, promote tissue remodeling, angiogenesis, 
tumor progression and immune regulation, whereas Mph1 participates in Th1 
responses and are protective against tumors and organisms (44). 
Recently other Mph subsets have been described. Mph2d are the results of 
switching from Mph1 as a response to adenosine A2A receptor signaling 
induced by TLR agonists (45). These Mph have decreased expression of pro-
inflammatory cytokines, including IL-12 and TNF-α, while concurrently produce 
high levels of IL-10 and vascular endothelial growth factor. Mox Mph are 
induced by ox-PL 1-palmitoyl- 2arachidonoyl-sn-glycero-3-phosphorylcholine, 
resulting in a population of Mph that express an unique set of genes like heme 
oxygenase-1 (HO-1) and thioredoxin-reductase in a Nrf2 dependent manner 
(36). Mha macrophages are differentiated from monocytes using hapto-
hemoglobin complexes or oxidized red blood cells leading to the up-regulation 
of CD163, HO-1 and IL-10 in an Nrf2-dependent manner, suggesting that these 
two subsets might be related (46). In addition, Mph4 have combined features 
of Mph1 and Mph2 and were shown to be CSF/CXCL4-dependent (47). These 
Mph have a weak phagocytic capacity, but their function remains poorly 
understood. Mox, Mha and Mph4 have until now been poorly characterized. 
Considering the heterogeneous expression of cell surface markers in Mph, the 
number of Mph-subpopulations could be infinite (2).
Distinguishing between Mph1 and Mph2 subsets
Considering the great heterogeneity, it is a major challenge to distinguish 
different Mph subsets. This characterization is mainly based on the expression 
of cell surface markers as well as their cytokine and chemokine production 
profile (Table 1). Specific Mph2 markers in mice, arginase-1, FIZZ1, Ym1, 
Ym2 and MRC1 have been identified both in vivo and in vitro (1,48), whereas 
establishing specific markers for human Mph2 is still an ongoing challenge. 
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and CCL18 have been described (1,49-51). In general, the high expression of 
cell surface markers CD163 and CD206 on Mph2 is used to distinguish Mph1 
and Mph2, although different levels have been reported depending on the 
Mph2 subtype (52-55). Mph1 and Mph2 produce distinct cytokines: Mph1 
show high TNF-α, IL-6, IL-12, and IL-23 production and low IL-10 levels, whereas 
Mph2 typically produce high levels of IL-10 and TGF-β (40,41,53,55,56) (Table 
1). In addition, the chemokine production of Mph1 and Mph2 is different. Mph1 
produces inflammatory CC chemokines and IFN-γ-responsive chemokines 
CCL5 (RANTES), CXCL9, CXCL10 (IFN-γ-IP-10), and CXCL16 that will recruit 
Th1, Tc1, and NK cells and thus a type 1 immune response (39,56). IL-4 and 
IL-10 differentiated Mph2 will inhibit the expression of most of these 
chemokines, and thereby limiting inflammation. M-CSF, IL-4, and IL-10 all 
induce CCL2 (MCP-1). IL-4 induces CCL17, CCL24, and CCL22, which will be 
inhibited by IFN-γ differentiated Mph1 (39,57). CCL22 binds to CCR4 which 
is expressed on Th2 lymphocytes, thereby amplifying the Th2 response (58). 
Taken together, the cytokine and chemokine production of Mph1 will lead to a 
Th1 response, whereas that of Mph2 will lead a Th2 response. 
The transcriptional regulation during differentiation is also different in Mph1 
and Mph2 (Table 1). The transcription factor PU.1 is essential to Mph lineage 
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commitment and Mph-specific gene expression (59). Transcription factors are 
also involved in the Mph polarization. The transcription factors involved in Mph1 
polarization are NF-kB, activator protein-1, CCAAT/enhancer-binding protein-α 
(C/EBP-α), and interferon regulatory factor (IRF)5, whereas STAT6, peroxisome 
proliferator-activated receptor γ (PPARγ), IRF4, C/EBP-β, and Krüppel-like 
factor 4 (KLF4) are associated with Mph2 polarization (60). STAT6 induces the 
transcription factor PPARγ, which acts together with STAT6 to regulate Mph2-
specific genes and polarization (61). KLF4 was found to cooperate with STAT6 
to induce an Mph2 profile, while inhibiting Mph1 targets (62). IRF4 has been 
implicated in Mph2 polarization, whereas IRF5 participates in the activation of 
genes encoding pro-inflammatory cytokines and represses the gene encoding 
IL-10, resulting into Mph1 activation (56,63).
 
ROS producing capacity of Mph1 and Mph2
A distinctive difference described between Mph1 and Mph2 is the high 
reactive oxygen species (ROS) production by Mph1, while IL-4 differentiated 
Mph2 are described as non-ROS producing cell (40,53,57,64). ROS generated 
by Mph are usually associated with oxidative stress (65). However, it has been 
shown that ROS produced in the immunological synapse or produced in lower 
amounts can inhibit T cell activation, or can serve as second messenger in 
various signaling pathways (66-69). These data indicate that the exact role of 
Mph-derived ROS in the immune system needs to be resolved.
 
Reactive oxygen species 
Important insights into the potential role of ROS in immune regulation were 
obtained in experimental models of autoimmunity, where Dark Agouti (DA) 
rats were found to be more prone to develop RA compared with other rat 
strains. Genetic studies identified a naturally occurring polymorphism in Ncf1, 
component of the NADPH oxidase complex, linked to the severity of arthritis 
in rats (70). This polymorphism resulted in a reduced ROS production and 
promoted the activation of arthritogenic T cells. 
 
Phagocytic NADPH oxidase complex 
ROS are produced by the mitochondrial electron transport chain, peroxisomes, 
xanthine oxidase, endoplasmic reticulum and the NADPH oxidases. There 
are seven family members of the NADPH oxidases, namely NOX complexes 
1-5, and DUOX 1 and 2. The main producers of phagocytic NOX2-derived 
ROS are PMN and Mph. The NOX2 complex is responsible for the oxidative 
burst, causing a sufficient concentration of ROS in the phagosome, required 
to kill pathogens. NOX2 consists of multiple components: the membrane-
bound cytochrome-b558 consisting of gp91phox and p22phox, and the cytosolic 
components p47phox (Ncf1), p67phox, and p40phox, and the small GTPase Rac. Upon 
phosphorylation p47phox, together with p67phox and p40phox, form the NOX2 
complex in the membrane by interacting with p22phox and gp91phox, resulting 
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is then further processed to generate more reactive metabolites like hydroxyl 
radical, after interaction with transition metal ions, and hypochlorous acid, 
which is catalyzed by myeloperoxidase. NOX2-derived ROS are generated in 
the plasma membrane, but ROS production can also occur within intracellular 
organelles, although the exact compartment is yet to be determined 
(71). 
Chronic granulomatous disease (CGD) is a disease that develops when 
mutations in one of the NOX2 components occur, resulting in defective ROS 
production. At this moment, mutations in the CYBB (gp91phox), CYBA (p22phox), 
NCF1 (p47phox), NCF2 (p67phox), and NCF4 (p40phox) genes have been described 
(72,73). The predominant form of CGD, comprising about 70% of cases, results 
from mutations in gp91phox which are inherited in an X-linked recessive 
manner, whereas mutations in the other genes are inherited in an autosomal 
recessive manner (73). CGD patients have a ROS production of 0.1 – 27% 
compared to normal levels (74). The X-linked recessive cases are more severe 
than autosomal recessive cases, since these patients have a lower residual 
ROS production. In addition, with a modest residual ROS production there is 
a greater probability of long-term survival compared with those having little 
residual ROS levels (74). The consequences of the diminished or abrogated 
oxidative burst by the NOX2 complex in CGD patients are recurrent bacterial 
and fungal infections, as well as granuloma formation (75). In addition these 
patients suffer more often from autoimmune diseases such as RA or systemic 
lupus erythematosis compared to the normal population (76,77). Since a 
hyperinflammatory phenotype is presented under non-infectious conditions 
with suboptimal ROS production, this indicates that normal phagocytic ROS 
production suppress pro-inflammatory gene transcription and preserve 
homeostasis (71). Interestingly, CGD patients have defective apoptosis after 
phagocytosis, as a result of reduced induction of the pro-apoptotic protein 
BAX (78). This study indicates that ROS are involved in the resolution of 
inflammation as well. 
Redox signaling
ROS are being produced as a result of normal cell physiology or due to ageing 
or stress. As defense against ROS, cells have anti-oxidants, like glutathione, 
Vitamins C and E, superoxide dismutases, catalase, peroxidases, thioredoxins, 
glutaredoxins, and peroxiredoxins (79). Oxidative stress generally involves non-
specific oxidation of a wide variety of molecules and is associated with higher 
oxidation states like sulfinic and sulfonic acid, causing irreversibly damage. 
There are strong indications that oxidative stress is an important pathogenic 
mechanism in various disorders, including cancer, ageing, atherosclerosis, 
diabetes, and ischemia-reperfusion injury (80). Thus eliminating ROS by anti-
oxidants would potentially be beneficial. However, it has been demonstrated 
that antioxidants could not improve the disease course of RA or atherosclerosis 
(81,82). Even more so, the use of pro-oxidant phytol, causing increased ROS 
production, actually decreased inflammation in animals with arthritis (83). 
ROS serve as second messenger in various signaling pathways by changing 
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specific proteins. Hydrogen peroxide oxidizes thiol groups of protein cysteine 
residues forming disulfides either with other protein cysteines or with low-
molecular weight thiols like glutathione, or forming sulfenic acids. Only a 
subset of cysteine residues in proteins is susceptible to oxidation, indicating the 
specificity of the reactions. These redox changes are in many cases associated 
with altered activity and effects on signaling pathways or cellular processes. In 
bacteria, the transcriptional activator OxyR, is directly oxidized in response to 
hydrogen peroxide (84). Even though both the oxidized and reduced OxyR 
are able to bind DNA, only the oxidized form can activate the transcription 
of antioxidant genes. In eukaryotes, proteins susceptible to thiol oxidation 
are protein tyrosine phosphatases (PTPs), kinases, and some transcription 
factors (85,86). PTPs are inactivated after oxidation, resulting in the activation 
of downstream signaling pathways. The transcription factor family NF-kB is 
also under redox control, although both oxidation and reduction by ROS are 
implicated in the activation process (87). In addition, the stress-responsive 
transcription factor Nrf2 is activated by the oxidation of its inhibitory partner 
Keap1, thereby disassociating Nrf2 from the complex, leading to the activation 
of target genes like HO-1 and superoxide dismutase (88). Since the above 
mentioned transcription factors also control the expression of genes involved 
in immunity and inflammation, understanding redox signaling is of great 
importance.
Effects of oxidation on signaling via the T cell receptor (TCR) has also been 
reported. In RA patients T cell hyporesponsiveness was dependent on the 
translocation of linker for activation (LAT) of T cells induced by oxidative stress, 
which impaired the TCR signaling (89). Also TCR zeta and p56lck signaling 
molecules have been indicated as redox targets after structural changes were 
observed after oxidation (90). The integrin VLA-4 was identified as redox target, 
which is a co-stimulatory molecule in the immunologic synapse (91). These data 
indicate an important role for ROS in modifying the T cell response, directly 
associating redox-dependent TCR signaling regulation and T cell function. 
This was also shown in a rat model where decreased ability to produce ROS 
in DA rats was associated with increased numbers of thiol groups present on 
the cell surface of their T cells (92). In addition, T cells from rats with normal 
ROS production could only transfer arthritis after increasing the number of thiol 
groups, whereas T cells from DA rats became less arthritogenic after decreasing 
the thiol groups (92). 
ROS producing capacity of myeloid cells
During phagocytosis of pathogens, neutrophils produce NOX2-derived ROS 
to kill microorganisms (3). Interestingly, when comparing neutrophils from 
CGD patients with healthy controls increased expression of genes encoding 
for inflammation and host defense were observed, whereas anti-inflammatory 
mediators were down-regulated (78). A more recently discovered process 
stimulated by ROS is the formation of neutrophil extracellular traps (NETs) 
(93). Stimulated neutrophils generate these NETs in order to catch and kill 
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NOX2-derived ROS in the antimicrobial response (93). 
Myeloid-derived suppressor cells (MDSC), a recently identified population of 
myeloid cells, continuously produce inflammatory mediators, like IL-1, IL-6, and 
nitric oxide, but also ROS (94,95). MDSC are predominantly found in tumour 
bearing patients where they proliferate and stay activated due to chronic 
inflammation in the tumour environment. ROS production of MDSC is mediated 
through increased activity of NOX2. The role of ROS in T cell suppression 
was confirmed when MDSC from gp91-/- mice were not able to induce T cell 
tolerance (96). MDSC, via generation of ROS and peroxynitrite (O2⋅− and NO 
interaction), induced the modification of the peptide-MHC binding of T cells 
rendering them unresponsive to antigen-specific stimulation (96).
ROS producing capacity of Mph
The Ncf1 gene, encoding the NOX2 protein p47phox,was responsible for DA rats 
being more prone to develop RA or multiple sclerosis compared with other rat 
strains (70). This indicates that a lack of ROS production in these rats caused 
a higher susceptibility to disease. A mutation in the Ncf1 gene in the mouse 
had similar results in models of RA and multiple sclerosis showing increased 
susceptibility and severity due to reduced oxidative burst (97). Interestingly, 
in rats with a reduced ROS producing capacity the increased susceptibility to 
pristane-induced arthritis was mediated in a T cell-dependent fashion (98). 
However, T cells have a very low NOX2 expression production, if any, suggesting 
that other cells were involved. Among murine APCs, Mph were the highest ROS 
producing cells compared with B cells and DCs (99). In addition, mice expressing 
functional p47phox only in their Mph were similarly protected against collagen 
induced arthritis compared to fully functional wild type mice (99). These data 
indicate that ROS derived from Mph inhibit T cell responses. Mn/Mph NADPH 
oxidase was also identified playing a central role in controlling fungal infecting 
and limiting lung inflammation in a mouse model (100). Furthermore, mice with 
Mn/Mph expressing functional Ncf1 were protected against bacterial infections 
(101). These data indicate an anti-inflammatory role for Mph-derived ROS. 
However, IL-4 differentiated Mph2 have reduced respiratory burst, whereas 
Mph1 are known for their ROS-producing capacity (45,59,68,83). Mph-derived 
ROS are associated with oxidative stress (84), and therefore linked to Mph1, but 
apparently there is a dual role for Mph-derived ROS. The function of ROS in the 
immune system is thus not simply antimicrobial, but NOX2-derived ROS are 
also involved in immune modulation, cellular signaling, chemotaxis, antigen 
cross-presentation and in inducing autophagy (102).
Scope of thesis
ROS are implicated in cell signaling and also play a role in immune-modulating 
processes. Anti-inflammatory Mph could inhibit T cell responses in a ROS-
dependent fashion, which was shown using transgenic mice expressing 
functional Ncf1 restricted to Mph. However, there is limited information on 
the T cell inhibitory role of Mph-derived ROS in the human setting. For that 
reason the scope of this thesis was to obtain better insight in the role of 
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ROS being produced by anti-inflammatory Mph2 in immune regulation. 
First we investigated the human anti-inflammatory Mph2 for their functional 
capacity in a ROS-dependent fashion in Chapter 2. The anti-inflammatory 
potential of the ROS-producing capacity of Mph2 led us to investigate the 
possibility of using Mph2 as cellular therapy, therefore Chapter 3 focuses 
on the effect of several commonly used immunosuppressive drugs on Mph1 
and Mph2 regarding ROS production and the subsequent effect on T cell 
responses. Since inhibition of T cell activation in a ROS-dependent fashion 
was observed, we investigated a potential mechanism by which Mph2-derived 
ROS could affect T cell function in Chapter 4. Since an observed protective 
role of macrophages-derived ROS in autoimmune diseases was observed, in 
Chapter 5 we investigated the impact of ROS production on the inflammatory 
response in a renal allograft transplantation model. Chapter 6 summarizes the 
studies presented in this thesis and discusses the implications of these findings 
as well as some unpublished data, and further discusses the role of Mph2-
derived ROS in immune modulation.
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Abstract
The phagocyte NAPDH-oxidase complex consists of several phagocyte oxidase 
(phox) proteins, generating reactive oxygen species (ROS) upon activation. ROS are 
involved in the defense against microorganisms but also in immune regulation. 
Defective ROS formation leads to chronic granulomatous disease (CGD) with 
increased incidence of autoimmunity and disturbed resolution of inflammation. 
Because regulatory T cells (Tregs) suppress autoimmune T-cell responses and 
are crucial in down-regulating immune responses, we hypothesized that ROS 
deficiency may lead to decreased Treg induction. Previously, we showed that 
in p47phox-mutated mice, reconstitution of macrophages (Mph) with ROS-
producing capacity was sufficient to protect the mice from arthritis. Now, we 
present evidence that Mph-derived ROS induce Tregs. In vitro, we showed that 
Mph ROS-dependently induce Treg, using an NADPH-oxidase inhibitor. This 
was confirmed genetically: rat or human CGD Mph with mutated p47phox or 
gp91phox, displayed hampered Treg induction and T-cell suppression. However, 
basal Treg numbers in these subjects were comparable to controls, indicating 
a role for ROS in induction of peripheral Treg. Induction of allogeneic delayed-
type hypersensitivity with p47phox-mutated Mph confirmed the importance of 
Mph-derived ROS in Treg induction in vivo. We conclude that NAPDH oxidase 
activity in Mph is important for the induction of Tregs to regulate T cell-mediated 
inflammation.
Introduction
Reactive oxygen species (ROS) are not only harmful and mediators of oxidative 
stress, but also have immune regulatory functions, especially when produced in 
lower amounts (1,2,3). The mechanisms of how ROS affect the immune system 
are just beginning to become clear. For example, mitochondrial ROS oxidize 
released HMGB-1 during apoptosis, thereby preventing immune activation 
and allowing induction of tolerance (4), and myeloid-derived suppressor 
cells suppress antitumor T-cell responses in a phagocytic NADPH-oxidase 
(Nox2) complex-dependent way (5). This Nox2 complex consists of multiple 
components (i.e. the membrane-expressed cytochrome-b558 consisting 
of gp91phox and p22phox and the cytosolic components p47phox, p67phox and 
p40phox). Chronic granulomatous disease (CGD) develops when any of these 
components is absent or functionally hampered and ROS production is 
defective. CGD is characterized by recurrent bacterial and fungal infections and 
abnormal granuloma formation. These granulomas are mostly sterile and often 
respond to steroid therapy without antibiotics (6). In addition, CGD patients 
suffer more frequently from autoimmune diseases as compared to the healthy 
population (7,8). These features point to a defect in immune regulation due to 
the absence of ROS. 
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We observed previously that mice and rats with alleles of the neutrophil cytosolic 
factor 1 (Ncf1) gene (encoding p47phox) that encode a less functional Nox2 and 
thus lower ROS production are more susceptible to induced autoimmune 
diseases than are their wild-type littermates (9,10). This observation is in line 
with observations in CGD patients. Interestingly, the reduced ROS-producing 
capacity in our congenic rat model mediated higher susceptibility to pristane-
induced arthritis in a T-cell-dependent fashion (9,11). However, T cells express 
no or only very low levels of Nox2, suggesting that other cells determine the 
T-cell response by producing ROS (12). One study, however, does show low 
levels of Nox2 in T cells (13). Because antigen-presenting cells (APC) interact 
with T cells during antigen presentation, and APC express Nox2 they may affect 
T-cell responses via ROS production. Indeed, ROS produced during antigen 
presentation affect the immune response (14,15) by interfering in signal 
transduction (16,17). In addition, ROS generated in phagosomes/endosomes 
determines the ability to cross-present antigen, both in mice and humans 
(18,19). We showed that amongst murine APCs, macrophages (Mph) were 
most efficient at producing ROS (20). Transgenic mice expressing functional 
p47phox only in Mph on a p47phox mutated background were equally protected 
against collagen-induced arthritis (CIA) as their fully wild-type littermates. 
These observations indicate that Mph-derived ROS are sufficient to inhibit 
T-cell responses (20). 
Regulatory T cells (Tregs) can suppress activation and proliferation of effector 
T cells and thereby diminish immune responses. Autoimmunity can therefore 
be the result of a defective Treg  system (21) and successful treatment of 
autoimmune disease with Tregs has been reported in mouse models (22,23). 
We hypothesized that if Mph-derived ROS prevent T-cell-mediated immune 
responses, it could do so by inducing Tregs. Previously we showed that 
antiinflammatory Mph can induce potent Tregs, in contrast to proinflammatory 
Mph (24). Here we here investigated whether Mph-derived ROS influence 
induction of Tregs in humans in vitro as well as in rats in vivo. We observed 
that Mph can induce Tregs in a ROS-dependent fashion in vitro and, more 
importantly, that Mph from ROS deficient CGD patients are significantly 
less efficient in inducing Tregs. We conclude that Mph can modulate T-cell 
responses by producing ROS and induce Tregs in a ROS-dependent fashion.
Results
Human Mph produce ROS upon stimulation
To investigate the role of ROS in antigen presentation by different APC, the 
expression of two Nox2 members was determined: p47phox (Ncf1) and gp91phox 
(Cybb) in human dendritic cells (DC) and in Mph colony-stimulating factor 
(M-CSF)-differentiated Mph. mRNA expression for both p47phox and gp91phox 
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FACS analysis we observed that the expression of gp91phox protein was very low 
in DC, whereas p47phox was clearly present. In contrast, Mph showed significant 
expression of both gp91phox and p47phox (Fig 1B). Functionally, human Mph 
efficiently generated ROS upon phorbol 12-myristate 13-acetate (PMA) 
stimulation (Fig 1C,D). In contrast, DC hardly produced ROS, in line with the 
low of gp91phox expression. Mph differentiated in GM-CSF (proinflammatory 
Mph) produced only marginal amounts of ROS (Fig S1A) The ROS production 
by Mph could be blocked to background levels with apocynin; an inhibitor of 
Nox2 that binds p47phox and prevents translocation to the membrane (Fig 1E). 
Mph suppress T-cell responses by producing ROS
To investigate the suppressive capacity of ROS produced by APC on T-cell 



























































































































Figure 1: Mph produce ROS. (A) mRNA and (B) protein expression levels of the two most important NADPH 
oxidase complex components, p47phox and gp91phox, determined in DC and Mph by RT-PCR and flowcytometry, 
respectively. In (A) mRNA expression levels were corrected for GAPDH expression and expression levels of DC 
were set to 1. (B) shows the ratio between specific staining and isotype control. Shown are average + SD of the 
relative expression levels of 4 experiments with cells from 4 different donors. (C) The capacity of DC and Mph to 
produce ROS was measured after PMA stimulation. Shown are average + SD of 6-10 independent experiments; 
the conditions after PMA stimulation or stimulated with vehicle (DMSO) are shown. (D) Representative examples 
of FACS histograms of ROS production, measured by DHR123 fluorescence, by DC (left) and Mph (right) after 
PMA (dotted line) or DMSO (ctr; solid line) stimulation. (E) Production of ROS by DC and Mph was measured 
after PMA or vehicle activation and in the absence or presence of the specific p47phox inhibitor apocynin (1 mM). 
Average + SD of 3-4 independent experiments are shown, * = p<0.05.
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the presence of increasing numbers of Mph or DC. IFN-γ production and 
the proliferative response were determined at day 5. IFN-γ production (Fig 
2A,C,and Fig S1B) and, to a lesser extent, T cell proliferation (Fig 2D,F) were 
suppressed by Mph but not by DC. The Nox2-inhibitor apocynin abrogated the 
Mph-mediated suppressive effect in a dose-dependent manner (Fig 2B, C, E 
and F). GM-CSF differentiated proinflammatory Mph slightly suppressed T-cell 
activation, but this suppression was not reversible by apocynin and thus was 








Figure 2: Mph suppress T cell activation in a ROS-dependent fashion. (A, D) T cells (150.000) were activated 
with anti-CD3/28 Ab and Mph or DC were added in increasing numbers (x-axes). After 5 days of coculture IFN-γ 
production (A) and proliferation (D) were determined by ELISA and 3H thymidine incorporation, respectively. 
Shown are the average + SD of triplicates within one representative experiment. (B, E) 150.000 T cells and 25.000 
Mph were cocultured in absence or presence of different concentrations of apocynin (x-axis) to study the effect 
of ROS on Mph mediated T cell suppression. After 5 days of coculture IFN-γ production (B) and proliferation (E) 
were determined by ELISA and 3H thymidine incorporation, respectively. Representative experiments are shown.
(C, F) Similar experiments as in A,B,D,E, but the average with SD of 3-4 independent experiments are
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Mph induce Tregs in a ROS-dependent fashion
Mph differentiated with M-CSF induce CD4+CD25+FoxP3+ Tregs (24). The 
observed ROS-dependent suppression of T-cell activation by Mph could 
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Figure 3: Mph induce Tregs via ROS. (A) Expression of FoxP3 within CD3+CD4+CD25+ population of T cells 
primed with Mph in absence (left) or presence (right) of apocynin. (B) Priming of CD4+CD25- T cells with Mph 
in the presence or absence of apocynin for 7 days, followed by the analysis of the percentage of FoxP3+ cells 
amongst CD3+CD4+CD25+ cells. The white bar represents CD4+CD25- T cells cultured similarly, but without Mph. 
The average + SD of 3 experiments is shown. (C) T cells were primed with (left panel) or without (right panel) 
Mph in presence or absence of apocynin (1 mM). After 5 days, these T cells were used as suppressor cells (S) 
and combined with responder T cells (R) and irradiated feeder cells (F). Proliferation of R was assessed by 3H 
thymidine incorporation (C) or by determining CFSE dilution (D). In C, average + SD of 4 experiments are shown. 
In D, the 1:1 ratio from a representative experiment out of 3 is shown, as well as the control condition without S, 
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Figure 4: CGD macrophages induce less Tregs. (A) The % of FoxP3+ cells amongst CD4+CD25+ in peripheral 
blood of CGD patients and healthy controls. (B) ROS production by Mph differentiated from healthy control 
or CGD monocytes, as determined by flow cytometry after DHR123 staining. The ratio of ROS production after 
stimulation with PMA or DMSO is depicted. (C) 106 CD4+CD25- T cells per condition, from a single allogeneic 
donor, were primed with Mph from either CGD patients or controls in presence of anti-CD3/28 Ab. After 5 days 
the number of viable T cells was determined. (D) Represenative picture showing the T cell clustering observed 
after activation with anti-CD3/CD28 in presence of ctr Mph (upper) or Mph derived from CGD patients (lower). 
The bars represent 25 μm. (E) T cells primed with Mph derived from CGD patients or controls were analyzed for 
the percentage of FoxP3+ cells amongst CD4+CD25+ by flow cytometry. (F) CFSE-labeled responder cells were 
cocultured with the Mph-primed T cells and irradiated feeder cells in presence of anti-CD3/28 and dilution of 
CFSE was measured by flow cytometry after 4 days. (G) In parallel experiments, 3H thymidine incorporation was 
determined. Grey dots are control conditions in the absence of Mph-primed suppressor T cells but with double 
amounts of responder cells (F2R), to correct for crowding effects. In the supernatants of this suppression assay 
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Figure 5: Mph suppress DTH reponses in vivo in a ROS-dependent fashion. (A) Rat BM cells were cultured with 
rat GM-CSF and IL-4 or human M-CSF to obtain DC and Mph, respectively. ROS production by PMA-stimulated 
DC and Mph generated from DA.Ncf1DA/DA or congenic Ncf1-wildtype DA.Ncf1E3/E3 rats was measured by DHR123 
staining. Average + SD of 4 experiments are shown. (B) Treg gating strategy on peripheral blood. (C) The % of 
FoxP3+ cells amongst CD3+CD4+CD25+ in peripheral blood of naïve DA.Ncf1E3/E3 (E3/E3) rats or DA.Ncf1DA/DA (DA/DA) 
rats. (D) Lewis rats were primed with Mph from either DA.Ncf1DA/DA (DA/DA) or DA.Ncf1E3/E3 rats (E3/E3) or PBS at day 0. 
At day 11, the % of FoxP3+ amongst CD3+CD4+CD25+ T cells was determined and compared to the levels in naïve 
Lewis rats. (E) After immunization at day 11 and challenging in the ear at day 25 with irradiated DA/DA splenocytes, 
the difference in ear thickness, as a measure for the DTH reaction, was determined at day 26. (F) The percentage 
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CD4+CD25- T cells were cocultured with Mph and anti-CD3/28 for 5 days and 
the percentage of FoxP3+ cells amongst CD3+CD4+CD25+ cells was assessed 
(Fig 3A left, 3B). The percentage of FoxP3+ cells amongst CD3+CD4+CD25+ was 
increased upon coculture of T cells with Mph, confirming their Treg inducing 
capacity. Addition of apocynin to these cultures significantly reduced the 
number of Tregs (Fig 3A right, 3B), demonstrating the ROS dependency of Treg 
induction. To determine the functional capacity of these Tregs, suppression 
assays were performed. CD4+CD25- T cells were primed by Mph for 5 days, 
in presence of anti-CD3/28 and in absence or presence of apocynin. These 
primed T cells were used as suppressor cells and combined with CD4+CD25- 
allogeneic carboxyfluorescein succinimidyl ester (CFSE)-labeled responder T 
cells and irradiated feeder cells. After 5 days, T cell proliferation was assessed 
by 3H thymidine incorporation and CFSE dilution. T cells primed with Mph 
suppressed proliferation of responder T cells in a dose dependent fashion. 
In line with the observed ROS dependence of FoxP3 induction, priming in 
presence of apocynin prevented this suppressive activity (Fig 3C, D). ROS 
dependency of this effect was confirmed further by the observation that 
GM-CSF differentiated Mph that hardly produced ROS did not induce Treg 
(Fig S2A, B).
Mph from CGD patients show disturbed Treg induction
To obtain genetic proof of the ROS-dependency of Treg induction, similar 
experiments were performed with Mph from CGD patients. The percentages of 
FoxP3+ cells amongst CD4+CD25+ cells were determined in peripheral blood 
of CGD patients and from healthy controls. No differences were observed (Fig 
4A). To study the role of ROS in induction of Treg by Mph, monocytes from 
CGD patients and controls were isolated and cultured in M-CSF to obtain Mph.
Mph from CGD patients and healthy controls showed similar morphology and 
expression levels of CD14 and CD163 (25), whereas the capacity to produce 
ROS was completely absent in CGD Mph (Fig 4B). Upon priming of CD4+CD25- 
T cells from one donor with either CGD or control Mph in presence of anti-
CD3/28, we observed that CGD Mph allowed significantly more T cell activation 
and expansion (Fig 4C and D). Moreover, CGD Mph induced significantly lower 
numbers of FoxP3+ T cells (Fig 4E) than did control Mph. In a suppression assay, 
we observed that T cells primed by CGD Mph showed reduced inhibition of 
responder T cell proliferation than did cells primed by control Mph (Fig 4F, 
G). In line with this observation, the levels of IFN-γ and IL-17 produced in 
these assays were significantly higher when suppressor cells were primed 
with CGD Mph than with control Mph (Fig 4H, I). These results provide genetic 
confirmation in human cells that production of ROS by Mph is involved in the 
induction of peripheral Tregs in human cells. 
Mph induce Tregs in vivo in a ROS-dependent fashion
To investigate whether Mph induce Treg in a ROS-dependent fashion in vivo, 
we used the congenic rat model (9). Dark Agouti (DA).Ncf1DA/DA rats have a 
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DA.Ncf1E3/E3 congenic rats express the allelic variant which leads to higher 
ROS production. First ROS production by Mph and DC cultured from bone 
marrow of both strains was determined. Similar to the human and murine 
(20) situation, Mph of the DA.Ncf1E3/E3 strain were able to produce significant 
levels of ROS after stimulation, whereas DC were far less efficient (Fig 5A). To 
compare circulating Treg numbers, FoxP3+ cells amongst CD3+CD4+CD25+ 
cells was measured, but no differences between the two strains were observed, 
similar to findings in CGD patients and controls (Fig 5B,C). To study the effect of 
Mph ROS on Treg induction and T cell responses in vivo, allogeneic Lewis rats 
were primed with Mph from either DA.Ncf1E3/E3 or DA.Ncf1DA/DA rats. Eleven days 
later, all rats were immunized with irradiated splenocytes from DA.Ncf1DA/DA
rats to boost the anti-DA response. At this time point Lewis rats primed with 
DA.Ncf1DA/DA Mph, had lower numbers of CD3+CD4+CD25+FoxP3+ cells than 
those primed with ROS-sufficient DA.Ncf1E3/E3 Mph (Fig 5D), whereas the 
number of activated T cells (CD4+CD25+) cells was comparable (Fig S3A). Two 
weeks later, all rats were challenged with irradiated DA.Ncf1DA/DA splenocytes 
in the ear, to evoke a delayed-typer hypersensitivity (DTH) response. After 
24 hours, rats initially primed with ROS producing DA.Ncf1E3/E3 Mph showed 
a significantly less ear swelling as compared to rats primed with Mph from 
DA.Ncf1DA/DA rats (Fig 5F). Moreover, these rats still showed higher levels of 
FoxP3+ cells in their peripheral blood (Fig 5G), whereas the number of activated 
T cells did not differ between groups (Fig S3B). These results indicate that Mph 
induce Tregs in a ROS-dependent fashion in vivo, thereby leading to lower 
T-cell responses.
Discussion
Here we show that, in both humans and rats, Mph-derived ROS suppress T-cell 
responses by induction of Tregs. This finding was confirmed by using Mph 
Figure S1: Anti-inflammatory Mph2 but not pro-inflammatory Mph1 suppress T cell activation in a ROS dependent 
fashion. (A) Proinflammatory Mph (Mph1) produce lower levels of ROS as compared to anti-inflammatory Mph2 as 
measured by DHR123 fluorescence by flow cytometry after stimulation with PMA. (B) Suppression of anti-CD3/28 
Ab induced T cell IFN-γ production by pro-inflammatory Mph1 is less efficient as compared to suppression by 
anti-inflammatory Mph2. (C) Apocynin (apo) prevents inhibition of T cell activation by anti-inflammatory Mph2 
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from CGD patients. Importantly, we show that Mph induces Tregs in a ROS-
dependent fashion both in vitro and in vivo.
ROS can inhibit T cell activation (14,15,26). For example, in cancer patients, 
granulocyte-derived H2O2 mediates impairment of T cell function (27). The 
mechanism how ROS affect T-cell responses is still quite unclear. Rats with 
defective ROS production because of an SNP in Ncf1, have more reduced 
proteins at their T-cell surfaces. The functional implications of these high cell-
surface thiol levels were shown by arthritis transfer experiments; decreasing 
the number of thiols on CD4+ T cell surfaces abrogated their ability to transfer 
disease from sick DA.Ncf1DA/DA rats to naïve DA.Ncf1E3/E3 rats (12). Alternatively, 
ROS may pass the cell membrane and affect signal transduction proteins such 
as ζ-chain-associated protein kinase 70 (ZAP70) and linker of activation of T 
cell (LAT) (28). Another role for ROS has been suggested in the kynurenine 
pathway of tryptophan catabolism. In ROS-deficient mice with aspergillosis an 
O2- dependent step in the kynurenine pathway was blocked, contributing to 








Figure S2: Mph2 but not Mph1 induce Treg in a ROS dependent fashion. (A) Priming of CD4+CD25- T cells with 
anti-inflammatory Mph2 but not with pro-inflammatory Mph1 induces FoxP3 expression by these T cells. (B) T 
cells primed with Mph2 but not when primed with Mph1 suppress proliferation of responder T cells in a ROS 
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On the other hand, CGD Mph previously have been shown to have a normal 
tryptophan metabolism (30) and recently the microsomal cytochrome b5 rather 
than O2- was recently indicated to activate indoleamine 2,3 dioxygenase (31). 
(However, this may vary among species.) Finally, it has been reported that ROS 
can induce apoptosis in T cells (32,33), thereby decreasing the number of 
activated T cells. In our studies we did not see increased levels of apoptosis 
upon coincubation of Mph and T cells, so it is unlikely that increased apoptosis 
is the reason for the observed inhibition of activation. APC may affect T cells 
during antigen presentation through the production of ROS. This activitiy 
may take place in the immunological synapse, hence creating a micromilieu 
that allows oxidation of specific proteins; however, this notion has yet to be 
investigated. DC generally are considered to be the most powerful APC (34). 
We show here, as was shown previously (20)(35), that DC are not very efficient 
at producing ROS. In contrast, the Mph we investigated were very efficient in 
producing ROS. These Mph are differentiated from monocytes with M-CSF and 
have an antiinflammatory phenotype (36,37,38). Our Mph2 and Mph1 may not 
represent exactly all Mph occurring in vivo, but they provided good polar models 
to answer our research question (39). We already showed that these Mph, unlike 
proinflammatory type Mph, are able to induce potent Tregs (24). Tregs play a 
critical role in the prevention of autoimmunity and resolution of inflammation 
(40). Because Mph prevented T cell-mediated autoimmunity in the mouse by 
producing ROS, we here studies the effect of ROS produced by Mph on T cell 
activation and Treg induction, both in CGD patients and in an Ncf1-mutated rat 
model. Although ROS may have direct effects on T cells by oxidation of certain 
intracellular or membrane-bound proteins important for T cell signaling, ROS 
may also induce Tregs through Mph. We chose to use T-cell activation by Mph 
in an allogeneic setting, to exclude effects of ROS on antigen processing and 
presentation, which have been described before (19). We showed that Mph 
induce Tregs from a CD4+CD25- population only when they were able to 
produce ROS. Both pharmacologic and genetic inhibition of ROS production 
abrogated the ability of Mph to induce Tregs. Interestingly, the percentages of 
Treg in peripheral blood of CGD patients vs control subjects or in DA.Ncf1DA/DA 
Figure S3: The number of activated T cells during DTH remains similar between groups. (A, B) The percentage 
of CD25+ cells amongst CD3+CD4+ cells 11 days (A) or 26 days (B) after priming the rats with DA.Ncf1DA/DA 
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vs DA.Ncf1E3/E3 rats were comparable. This observation suggests that, in contrast 
to peripheral Treg induction, the number of natural Treg induced in the thymus, 
is not affected by Mph ROS, although expansion of naturel Tregs in the Lewis 
rats in the DTH experiments could not be excluded. Previously we have shown 
that Tregs induced by antiinflammatory Mph use membrane-bound TGF-β for 
suppression (24). Although we did not address the role of TGF-β in this study, 
it has been reported previously that ROS can activate TGF-β (41,42). However, 
these ROS were not cell-derived, so it is unknown whether ROS produced by 
Mph upon interaction with a T cell has similar effects on membrane-bound 
TGF-β, and if such activation would affect Treg induction. It has also been shown 
that T cells themselves can produce ROS after anti-CD3/28 Ab activation and 
that these ROS activate TGF-β, leading to Treg induction (43). However, this 
ROS is produced intracellular and this mechanism probably is not comparable 
to our system. The exact mechanisms, however, still need to be investigated.
It is an attractive idea that, as long as activation signals remain below a certain 
threshold level, Mph prevent unwanted inflammation and autoimmunity by 
regulating T-cell responses via the production of ROS (3). Upon potent immune 
activation (e.g. efficient antigen presentation by DC), the immune suppressive 
effect of Mph may be overwhelmed. This hypothesis is in line with the observation 
that both patients with CGD and mice with a nonfunctional Nox2 are more 
prone to develop autoimmunity (8,10,44,29,45). This observation suggests 
that Mph-derived ROS may protect against (auto-) immune activation. Indeed, 
altered monocyte function due to aberrant inflammatory gene expression has 
been observed in CGD patients (46,47). It would be interesting to investigate 
if the increased autoimmunity and defective granuloma resolution in CGD 
patients result from a defect in Treg induction. Recently, a role for Treg in 
granuloma clearing was described in Wegener’s granulomatosis. Treg number 
and function were reduced in patients with this disease, and the reduction was 
most pronounced in subjects with most active disease (48).
To investigate if ROS production by Mph could also inhibit allogeneic T-cell 
responses in vivo, DTH experiments were performed in a rat model. These 
experiments showed that Mph can prevent T cell responses and induce 
Tregs in a ROS-dependent fashion in vivo, thereby decreasing the allogeneic 
response. We thus demonstrated that the ability to produce ROS by APC plays 
a critical role in determining whether these APC will activate or suppress T cells. 
In conclusion, we show that Mph, by producing ROS, suppress T-cell activation 
and induce Tregs both in vitro and in vivo. 
Methods
Animals
Rats were from Harlan (DA or Lewis; Horst, the Netherlands) or own breeding 
(DA.Ncf1E3/E3; founders originating from Medical Inflammation Research, 








03_chapter2_herzien.indd   37 26-08-14   17:00
38     •     Chapter 2
were used (DA.Ncf1DA/DA and DA.Ncf1E3/E3). Rats were used at 8-12 weeks of age 
and groups were sex and age matched. Rats were kept in polysterene cages 
and fed standard rodent chow. Animal experiments were approved by the 
committee of medical ethics (CEM) of the Leiden University Medical Center.
Patients
Peripheral blood was obtained from 5 CGD patients with mutations identified 
in the genes encoding p47phox (AR-CGD, homozygous Δdeletion in NCF1) or 
gp91phox (X-linked CGD, mutations in CYBB). Patients signed informed consent. 
PBMC were isolated as described below. The number of viable monocytes was 
not different from healthy controls. 
Myeloid cell culture & T cell isolation
Human: Monocytes were isolated from buffy coats by positive selection of 
CD14+ cells from the ficoll interphase by MACS (Miltenyi)(38). Monocytes were 
cultured for 7 days in either 10 ng/ml IL-4 plus 5 ng/ml GM-CSF (both from 
Biosource) to obtain DC or 5 ng/ml M-CSF or GM-CSF (R&D systems) to obtain 
Mph (38). Cells were cultured at 1.5x106cells per well in 6 wells plates and 
medium containing cytokines was refreshed twice. For DC, the non-adherent 
cells were used. Macrophages were harvested by gentle scraping after short 
trypsin incubation (3 min, 37°C). T cells were isolated from buffy coats by sheep 
red blood cell rosetting. For Treg experiments CD4+ were isolated by MACS 
(negative selection kit, Miltenyi). CD25+ depletion was performed by panning 
on petridishes coated with goat-anti-mouse Ab and capturing T cells positively 
labeled with anti-CD25 Ab. These cells were >90% CD4+ and >99% CD25-.
Rat: For rat, bone marrow cells were cultured in rat GM-CSF + rat IL-4 (Biosource) 
to obtain DC or in human M-CSF (5 ng/ml) to obtain Mph and refreshed every 
other day. The culture medium contained additional L-glutamine (2 mM) and 
fungizone but no β-mercaptoethanol. Cells were used after 7 days. T cells were 
isolated from spleens by magnetic sorting for CD3+ cells (Dynabeads).
MLR
150.000 allogeneic T cells were cocultured with irradiated (40 Gy) myeloid cells 
in an MLR in different ratios, with soluble anti-CD3 and anti-CD28 (IxE; 1 μg/ml 
and CLB-CD28/1; 0,25 μg/ml, both kindly provided by Prof L.A. Aarden). After 
5 days, supernatant was assayed for IFN-γ production (eBioscience) and cells 
were cultured for 16 hours in presence of 3H thymidine (0,5 μCi) and thymidine 
incorporation was determined as a measure for proliferation. Anti-CD28 alone 
had no effect and the Ab had no effect on myeloid cell proliferation in absence 
of T cells. Apocynin (Sigma) was used in concentration ranges up to 1 mM. 
Flowcytometry
Expression levels of surface proteins were measured by flowcytometry 
(FACScalibur, BD) after staining with specific conjugated Ab or unconjugated 
Ab detected by conjugated secondary Ab. ROS production was determined 
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by incubating the cells with dihydrorhodamine123 (DHR123), 5 μM in RPMI++ 
at 37°C for 10 min. Subsequently, oxidative burst was induced by adding PMA 
(200 ng/ml for 20 min at 37oC). Human and rat Tregs were detected by staining 
with anti-CD25-PE, anti-CD3-PerCP and anti-CD4-APC (BD). Subsequently, 
cells were permeabilized, fixed (BD) and stained with anti-FoxP3-FITC, or FITC 
labeled isotype control, according to the manual to the used kit (eBioscience). 
The lymphocyte fraction was selected and the % of FoxP3+ amongst 
CD3+CD4+CD25bright cells was determined. Apoptotic cells were determined 
by Annexin-V-FITC, propidium iodide (BD) double staining. Single and double 
positive cells were analyzed as being apoptotic and dead cells respectively. The 
expression levels of p47phox and gp91phox were also determined by intracellular 
staining as described above for FoxP3 staining using mouse-anti-human 
p47phox and gp91phox Ab (Santa Cruz Biotechnology), detected with goat-anti-
mouse-PE (DAKO). 
T cell suppression assay
CD4+CD25- T cells from one donor were cultured with macrophages from 
another donor for 5 days in a ratio of 6:1, in the presence of anti-CD3/28. After 
5 days, T cells were harvested and depleted for HLA ClassII+ cells and used as 
suppressor cells (S) (<1% Mph contamination). Freshly isolated CD4+CD25- T 
cells were used as responders, whereas CD4- cells from the same donor were 
irradiated (40 Gy) and used as feeder cells. R:F:S was ranging from 8:16:32 to 
8:16:1. A control condition with feeders and double the number of responder 
T cells (F2R) in stead of FR was taken along to correct for possible crowding 
effects in the absence of suppressor cells as present in experimental conditions. 
Cells were stimulated with a low dose of PHA (1 μg/ml) or anti-CD3/28 (49). 
After 5 days cells were labeled for 8-16 hr with 3H Thymidine and incorporated 
radioactivity was determined. Supernatant was subjected to cytokine analysis 
by ELISA or Luminex bead-based assay. In some experiments, responder 
cells were labeled with 5μM CFSE, and proliferation was determined by FACS 
analysis, by gating on the CFSE labeled population and quantifying the CFSE 
dilution.
mRNA isolation and Q-PCR
mRNA was isolated using a Qiagen kit . After making cDNA, semi quantitative 
PCRs were performed on a Biorad Icycler machine and the following primers were 
used: p47phox (Forward: cctgacgagacggaagac; Reverse: gggaagtagcctgtgacg), 
gp91phox (Forward: tagtgggagcagggattg; Reverse: tcaaaggcatgtgtgtcc). 
The following GAPDH primers were used for normalization: Forward 
ttccaggagcgagatccct and reverse cacccatgacgaacatggg.
DTH experiments
Priming of Lewis rats at day 0 was done by i.v. injection of 5x106 Mph generated 
from either DA.Ncf1E3/E3 or DA.Ncf1DA/DA. Rats were immunized 11 days later 
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determine the percentage of Tregs. After another 14 days, at day 25, rats were 
challenged in the left ear with irradiated splenocytes in PBS. The right ears 
were injected with PBS only. Ear swelling was measured before challenge and 
after 24 hours and was expressed as the difference in thickness between the 
challenged and the control ear.
Statistics
Results of different independent, although similarly performed, experiments 
were pooled, and the averages of the values were subjected to statistical 
analysis. Significant differences were determined using the Mann Whitney U 
test. P<0.05 was considered as significantly different.
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Abstract 
Macrophages have been demonstrated to suppress T cell 
responses by producing Reactive Oxygen Species (ROS) leading 
to the subsequent induction of T regulatory cells in a ROS-dependent manner. 
Macrophages may therefore be instrumental in down-regulating T cell responses 
in situations of exacerbated immune responses. Here we investigated the effect 
of immunosuppressive drugs on ROS production by macrophage subsets and 
the subsequent effects on T cell activation. Macrophage type 1 and 2 were 
differentiated with GM-CSF or M-CSF, in presence or absence of dexamethasone, 
cyclosporine A, FK506, rapamycin, or mycophenolic acid. The ROS producing 
capacity of fully differentiated Mph was highest in anti-inflammatory Mph2 and 
not affected by exposure to immunosuppressive drugs. However, presence of 
rapamycin during Mph2 differentiation decreased the ROS production of these 
cells. In contrast, other immunosuppressive drugs, with dexamethasone being 
the most potent, increased the ROS producing capacity of Mph2. Intriguingly 
although the ROS producing ability of Mph1 was unaffected, dexamethasone 
strongly increased the ROS producing capabilities of dendritic cells. Both at 
the mRNA and protein level we found that dexamethasone enhanced the 
expression of NOX2 protein p47phox. Functionally, dexamethasone further 
enhanced the capacity of Mph2 to suppress T cell mediated IFN-γ and IL-4 
production. In vivo, only in rats with normal ROS production (congenic 
DA.Ncf1E3/E3) it was observed that dexamethasone injection resulted in long-
lasting upregulation of ROS production by macrophages and induced higher 
levels of Treg in a ROS-dependent manner. In conclusion, we show that the 
anti-inflammatory drug dexamethasone increases the ROS producing capacity 
of macrophages.
Introduction
In recent years it has become evident that macrophages (Mph) can efficiently 
suppress T cell responses (Mantovani et al., 2004; Ricardo et al., 2008). 
Recently, we have shown that an important mechanism of this Mph induced 
T cell suppression is the production of Reactive Oxygen Species (ROS) by the 
phagocyte NADPH oxidase complex (NOX2 complex) (Hultqvist et al., 2009). 
In a mouse model for arthritis it was shown that mice were protected when 
macrophages expressing a functional NOX2 complex were present. In contrast 
littermates that did not express a functional NOX2 complex developed 
clinically overt disease (Gelderman et al., 2007). Subsequently, we showed in 
the human situation, that Mph with a potent ROS producing capacity suppress 
allogeneic T cell responses and induce Treg in a ROS dependent manner 
(Kraaij et al., 2010). This work was recently repeated in the mouse by others 
(Lee et al., 2011). Importantly, in a rat model ROS-producing Mph could, in 
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vivo, attenuate allogeneic delayed type hypersensitivity responses (Kraaij et 
al., 2010), suggesting that these Mph might induce specific T cell suppression. 
Patients with Chronic Granulomatous Disease (CGD) have mutations in 
various components of the NOX2 complex and suffer from recurrent bacterial 
infections, underlying the importance of the NOX2 complex in innate immunity 
(Segal et al., 2011). Interestingly, these patients are also characterized by 
chronic inflammation, increased autoimmunity and a hampered ability to 
control inflammation, thus suggesting a regulatory role for the NOX2 complex 
and the subsequent ROS production. 
In view of this unanticipated but critical role of NOX2 in immune regulation, it is 
important to investigate how the ROS producing capacity in Mph is regulated. 
Mph exist in different forms, including polarized Mph1 and Mph2 subsets 
with clearly distinct cytokine production and other functional characteristics 
(Mantovani et al., 2004; Ricardo et al., 2008). Monocytes differentiated in the 
presence of IFN-γ, LPS, or GM-CSF are known as the classical macrophages 
(Mph1) and are characterized by a high IL-12 production and the promotion 
of T helper cell type 1 (Th1) responses. On the other hand, Mph2 (alternatively 
activated macrophages) are induced by M-CSF, or IL-4/IL-13 among others, 
and generally have low pro-inflammatory cytokine levels and generate T 
helper cell type 2 (Th2) activation. Mph2 induced by M-CSF are known as 
anti-inflammatory Mph that express CD163 and downregulate costimulatory 
molecules upon activation (Verreck et al., 2006). Analysis of NOX2 expression 
and function in various Mph subsets will be relevant since ROS producing 
Mph may be instrumental in alleviating T cell responses in autoimmunity or by 
preventing allograft rejection in transplantation.
Immunosuppressive drugs (IS drugs) are commonly given to prevent T cell 
activation and graft rejection (Hansen et al., 2007; Nankivell and Chapman, 
2006). However, the effects of these drugs extend far beyond suppressing T 
cells alone, and antigen presenting cells like dendritic cells and Mph have also 
been shown to be affected (Weichhart and Saemann, 2009). These IS drugs have 
severe side-effects including nephrotoxicity and an increased risk of infections 
and malignancies. Dosing should thus be minimized and the development of 
alternative therapies with fewer side-effects is essential. Cellular therapy, eg 
with myeloid cells such as dendritic cells and macrophages (Stax et al., 2008; 
Morelli and Thomson, 2007; van Kooten et al., 2011), or mesenchymal stromal 
cells (Reinders et al., 2010) could be such an alternative by inducing donor-
specific immunosuppression. Since IS drugs may affect the immunosuppressive 
function of the cells administered, it is of major importance to unravel the effect 
of different IS drugs on potential therapeutical cells. In addition, these IS drugs 
may influence the phenotype and function of endogenous immunoregulatory 
cells and thereby affect the immune response (Hoogduijn et al., 2008). 
In the current study we investigated the effect of several commonly used 
IS drugs on different macrophage types regarding ROS production and 
the subsequent effect on T cell responses. We show that dexamethasone 
increases the expression of NOX2 proteins and the ROS producing capacity 
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ROS producing capacity of monocytes/macrophages in vivo, associated with 
increased numbers of circulating Treg. 
Materials and Methods
Animals 
Littermates were obtained by intercrossing F1 animals from a DA (Harlan) x 
DA.Ncf1E3/E3 cross (DA.Ncf1E3/E3 founders originating from Medical Inflammation 
Research, Karolinska Institute, Stockholm, Sweden) (Olofsson et al., 2003). 
Animals were used at 8-12 weeks of age. Animal experiments were approved by 
the committee of medical ethics (CEM) of the Leiden University Medical Center. 
Dexamethasone (0.15mg) (Pharmacy, LUMC) was injected intraperitoneally at 
day 0 and 4. Heparinized blood was drawn from the tail for FACS-analysis. At 
day 22 the rats were sacrificed with CO2.
Macrophage / Dendritic cell culture
Monocytes were isolated from buffy coats by CD14+ MACS-bead selection 
(>95% purity) (Miltenyi Biotec) (Xu et al., 2007). Monocytes were cultured for 7d 
in 5 ng/ml GM-CSF (Biosource;  Mph1), in 5 ng/ml M-CSF (R&D systems; Mph2), 
or in 5 ng/ml GM-CSF and 10 ng/ml IL-4 (Biosource; DC). Cells were cultured 
in 6 wells plates, 1.5x106 cells per well in RPMI with 10% FCS and penicillin/
streptomycin (RPMI++); medium and cytokines were refreshed twice. After 
short trypsinization, macrophages were harvested by gentle scraping. From 
the DC cultures only the floating cells were used. Cultures were performed 
with 1 μM dex, 5 nM rapamycin (Calbiochem), 100 ng/ml cyclosphorine 
(Novartis), 100 ng/ml FK506 (Tacrolimus, Astellas), 50 ng/ml mycophenolic 
acid (MPA, Sigma Aldrich, diluted in ethanol), or 50 μg/ml prednisolone 
(PharmaChem) for 7 days or for 48 hours starting at day 6. Drug concentrations 
were chosen based on other studies and on trough levels in patients (Heidt 
et al., 2010; Woltman et al., 2000). At day 6 cells were stimulated with 200 
ng/ml LPS for 16 hours to assess IL-6, IL-10, TNF-α (Sanquin) and IL-12p40 
(Biolegend) production by ELISA.
Flow cytometry
ROS production was determined by first staining with 5 μM dihydrorhodamine123 
(DHR123) for 10 min at 37°C in RPMI++ followed by stimulation with 200 ng/ml 
phorbol-12-myristate13-acetate (PMA) for 20 min at 37°C. Expression of CD14 
and CD163 was determined, using the appropriate isotype control, with anti-
CD14-PE (BD) or anti-CD163-PE (DAKO). Protein levels of p47phox and gp91phox 
were determined by intracellular staining. Cells were permeabilized, fixed 
(BD), and followed by staining with anti-p47phox (Santa Cruz), anti-gp91phox, or 
an isotype control (BD) which was detected with GαM-PE (DAKO). Cell surface 
molecule expression was assessed by flow cytometry using a FACSCalibur and 
BD CellQuest software (BD Biosciences).
Whole peripheral blood from rat was stained with OX42 (anti-CD11b) 
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and detected with GαM-Alexa647. CD11bdim cells were considered to be 
monocytes/macrophages and CD11bbright cells as neutrophils, this compared 
well with the ROS-producing capacity of these two populations. Rat Tregs were 
determined by staining with anti-CD25-PE, anti-CD3-PerCP and anti-CD4-APC 
(BD). Subsequently, cells were permeabilized, fixed (BD) and stained with anti-
FoxP3-FITC, or FITC labeled isotype control (both eBioscience). Cells were 
gated on the lymphocyte fraction and the percentage of FoxP3+ amongst 
CD3+CD4+CD25bright cells was determined. 
T cell suppression assays
 T cells (150,000) were cocultured with different ratios of allogeneic Mph with 
0.5 μg/ml anti-CD3 and 1 μg/ml anti-CD28 (IxE; 1 μg/ml and CLB-CD28/1; 
provided by Prof L.A. Aarden). After 5 days, the supernatants were harvested 
to evaluate IL-4 (Sanquin) and IFN-γ (Invitrogen) levels by ELISA. The cells 
were pulsed with 0.5 μCi 3H thymidine overnight and T cell proliferation was 
determined by measuring thymidine incorporation.
mRNA isolation and Quantitative PCR
mRNA was isolated using a Qiagen kit. After making cDNA, quantitative 
PCRs were performed on a Bio-Rad Icycler machine using the following 
primers: p47phox (Forward: CCTGACGAGACGGAAGAC; Reverse: 
GGGAAGTAGCCTGTG ACG), gp91phox (Forward: TAGTGGGAGCAGGGATTG; 
Reverse: TCAAAGGCATGTGTGTCC). The following GAPDH primers were 
used for normalization: Forward TTCCAGGAGCGAGATCCCT and reverse 
CACCCATGACGAACATGGG.
Statistics
Results of different independent, although similarly performed, experiments 
were averaged and subjected to statistical analysis. Significant differences 
were determined using the Mann-Whitney test. 
Results
3.1 Anti-inflammatory macrophages produce ROS
Pro-inflammatory Mph1 and anti-inflammatory Mph2 were differentiated 
from CD14+ human monocytes by cultivation for 7 days in GM-CSF or M-CSF 
respectively. Their capacity to produce ROS was determined by flow cytometry 
after staining with DHR123. Upon PMA stimulation, and in a side by side 
comparison, Mph2 were more efficient in producing ROS as compared to 
Mph1 (Fig. 1A,B) (Kraaij et al., 2010). In line with previous data, these Mph2 
express higher levels of CD14 and CD163 as compared to Mph1 (Fig. 1C), 
and produce significantly lower amounts of IL-6, IL-12p40 and TNF-α upon 
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production (Fig. 1E).
Next we investigated the effect of IS drugs on ROS production by Mph1 or 
Mph2. Differentiated Mph1 or Mph2 were exposed for 2 days to either 
dexamethasone (dex), cyclosporine A (CsA), FK506 (FK), rapamycin (rapa), 
or mycophenolic acid (MPA). The cell viability was not affected by these 
concentrations (not shown). Subsequently, PMA-induced ROS production was 
determined and directly compared with the ROS production by non-treated 
Mph. Of the drugs investigated, none elicited a remarkable effect on the ROS 
production by Mph2 (Fig. 1F). Also the low ROS producing capacity of Mph1 
(Fig. 1A,B) was not affected by IS exposure (data not shown).
Immunosuppressive drugs influence the ROS producing capacity 
of Mph2
We further investigated whether the presence of these IS drugs during 
macrophage differentiation had an affect on their ROS. The amount of viable 
cells obtained after 7 days of culture was unaffected by the doses of drugs 
used in these experiments (not shown). On day 7, upon PMA stimulation, the 
ROS production by Mph 2 was ascertained. For all experiments described we 
made a direct comparison with Mph which were unexposed to the drugs. We 
observed a small enhancing effect of MPA on the ROS producing ability of 
Mph1 (Fig. 2A). It should be noted that this increase of MPA is minor in view of 
the already low ROS producing capacity of Mph1. Rapa was the only drug that 
significantly downregulated the ROS production by Mph2 (Fig. 2B). In contrast, 
the ROS producing capacity of Mph2 was significantly enhanced by dex, CsA, 
FK, and MPA, with dex being the most potent. A similar augumentary feature 
was observed for prednisolone, as cells cultured in the presence of this drug 
yielded a higher ROS production (data not shown). The expression of CD163 
was increased when Mph2 were cultured in the presence of dex, as shown 
previously (Buechler et al., 2000), whereas no change was observed for CD14 
levels (Fig. 2C). We also observed a decreased LPS-induced IL-6 production in 
the presence of dex (Fig. 2D). Thus, culturing monocytes in the presence of dex 
promoted the differentiation towards ROS-producing macrophages. 
Previously we have shown that dexamethasone is a strong modulator of 
human monocyte-derived DC development, resulting in cells with tolerogenic 
properties (Woltman et al., 2000). Although immature DCs have a low ROS 








Figure 1: Anti-inflammatory Mph2 have higher ROS producing capacity. (A) FACS histograms of DHR123 
fluorescence after staining of Mph1 (left) and Mph2 (right) to detect ROS production after PMA stimulation. (B) 
ROS production as induced by PMA or in absence of stimulation (DMSO; vehicle control) was determined for 
Mph1 and Mph2 by flow cytometry. The GeoMeanX of DHR123 fluorescence is depicted on the y-axis. (C) Mph1 
and Mph2 were compared for the expression levels of CD14 and CD163 by flow cytometry. (D) IL-6, IL-12p40, and 
TNF-α production was determined for Mph1 and Mph2 by ELISA. (E) IL-10 production was determined for Mph1 
and Mph2 by ELISA. (F) The effect of different immunosuppressive drugs (dexamethasone (dex), cyclosporine 
A (CsA), FK506 (FK), rapamycin (rapa), and mycophenolic acid (MPA)) were tested on Mph2; drugs were 
added for 48 hours after differentiation for 6 days. Mean and SEM of 17-25 (B), 3-6 (C,D,E), 2-8 (F) independent 
experiments are shown. * P<0.05.
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production was observed in DCs when the cells were cultured in the presence 
of dex (Fig. 2E). 
Dexamethasone increases the expression of components of the 
NOX2 complex
To explain the increased ROS producing capacity of Mph2 and DC, we 
investigated expression of the major components of the NOX2 complex. 
Generation of DC in the presence of dex was shown to increase mRNA 
expression of p47phox and gp91phox, two essential NOX2 proteins (Fig. 3A). In line 
with this, we observed that also Mph2 cultured in the presence of dex showed 
increased expression of p47phox mRNA expression, although no change was 
observed for gp91phox (Fig. 3B). At the protein level we observed a trend with 
increased p47phox expression for both DC and Mph2 cultured in the presence 
of dex, although this was not statistically significant (Fig. 3C,D). No difference 
was observed with gp91phox protein levels (Fig. 3C,D). These results might 
contribute to the increased ROS producing capacity upon dex treatment.
Mph2 differentiated in presence of dex show decreased cytokine 
response
Previously we showed that Mph2 are able to suppress anti-CD3/28-induced 
T cell activation in a ROS-dependent manner (Kraaij et al., 2010). In view of 
the profound effects of dex we investigated if differentiation of Mph2 in the 
presence of dex affected their capacities to suppress T cells. T cells cocultured 
with increasing numbers of Mph2, showed slightly enhanced T cell proliferation 
at the lower ratios, whereas proliferation was suppressed by Mph2 at high 
ratios, as shown before (Fig. 4A) (Kraaij et al., 2010). However, this suppression 
was not amplified when Mph2 were generated in the presence of dex (Fig. 
4A,D). In the same cocultures we also measured IFN-γ and IL-4 production. 
Mph2 inhibited IFN-γ and IL-4 production at high ratios, whereas at low ratios 
specifically the IFN-γ production was strongly increased. Mph cultured in dex 
did not show this increase in IFN-γ production (Fig. 4B) and showed more 
efficient inhibition of IFN-γ and IL-4 at higher ratios (Fig. 4B,C). Thus in contrast 
to the proliferative response, the T cell mediated IFN-γ and IL-4 production 
was significantly suppressed by Mph2 cultured in dex as compared to regular 
Mph2 (Fig. 4D). 
Dex increases ROS production in vivo and induces Treg
We next studied the ability of dex to increase ROS production by Mph in 
vivo. We used the DA rat strain, which expresses two naturally occuring single 
nucleotide polymorphisms in the Ncf1 gene encoding p47phox, leading to a 
reduced ROS producing capacity (DA.Ncf1DA/DA) (Hultqvist et al., 2011). We 
used these rats in comparison with its congenic strain which have a normal 
level of ROS production (DA. Ncf1E3/E3) (Olofsson et al., 2003). Following 
injection of 0.15 mg dex (i.p.) at day 0 and day 4, the ROS producing capacity 
of monocytes/macrophages (CD11bdim) in peripheral blood in DA.Ncf1E3/E3 
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rats was significantly increased at days 5 and 7 (Fig. 5A). This trend, although 
not significant, was observed until day 22, showing a long-lasting effect of 
dex on the ROS producing capacity of these cells (Fig. 5A). No change in ROS 
producing capacity was seen in the DA.Ncf1DA/DA rats (Fig. 5A). Interestingly, 
the ability of neutrophils to produce ROS at day 5 was unaffected by dex in the 
DA.Ncf1E3/E3 rats (Fig. 5B). 
Since we previously found that macrophage-derived ROS contributes 
to Treg induction (Kraaij et al., 2010), we investigated the percentage of 
CD3+CD4+CD25brightFoxP3+ cells after injection with dex in both rat strains. 
We observed that at day 5 the percentage of Tregs was increased in rats with 
normal ROS production, but not in the rats with low ROS producing capacity 
(Fig. 5D). Thus increased numbers of Tregs upon administration of dex 
coincided with the dex-induced increase in the ROS producing capabilities of 









Figure 2: Dex increases ROS producing capacity. (A, B) The effects of different immunosuppressive drugs (dex, 
CsA, FK, rapa, and MPA) during Mph differentiation were tested on ROS producing capacity. ROS production after 
PMA stimulation for both Mph1 (A) and Mph2 (B) is shown. Figures A and B both depict the relative effect of the 
drug(s): the ROS producing capacity of Mph differentiated in presence of drugs is divided by the ROS producing 
capacity of Mph differentiated in absence of drugs (no effect gives a value of 1). Mean with SEM are shown in all 
cases, of 2-8 independent experiments. (C) The effect of dex during Mph2 differentiation was tested for CD14 
and CD163 expression by flow cytometry. (D) The effect of dex during Mph2 differentiation on IL-6 production 
was determined by ELISA. Figures C and D both depict the relative effect of dex: expression/production of Mph2 
differentiated in presence of dex is divided by the expression/production of Mph2 differentiated in absence of 
dex. Mean with SD are shown of 4-6 independent experiments. (E) Relative ROS production induced by PMA or 
in absence of stimulation (DMSO; vehicle control) was determined for DC and dexDC by flow cytometry. Mean 
with SEM are shown in all cases of 3-5 independent experiments. * P<0.05, **P<0.005.
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Discussion
In the present study we show that the corticosteroid dexamethasone, one of the 
strongest and widely used anti-inflammatory drugs, is able to enhance the ROS 
producing capacity of macrophages and dendritic cells. This increased ROS 
production was most pronounced in the anti-inflammatory Mph2 subset and was 
demonstrated in human cells in vitro as well as in rat monocytes/macrophages 
in vivo. Dex treatment coincided with an increased ability to suppress T cell 
activation in vitro and with the number of circulating Treg in rats. These findings 
provide an additional mechanism of the immunosuppressive action of steroids 
and further underline the recently described and unanticipated regulatory 
function of NOX2-mediated ROS when produced by antigen presenting cells 
Figure 3: Dexamethasone increases the expression of components of the NOX2 complex. (A, B) mRNA levels 
for p47phox and gp91phox as determined by qPCR. In every experiment, normalized mRNA expression for DC and 
Mph2 was put on 1.0 and dexDC/dexMph2 expression was related to that value. (C, D) Protein levels for p47phox 
and gp91phox were determined by flow cytometry after intracellular staining. Mean with SEM are shown in all cases 
of 3-5 independent experiments. * P<0.05.
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(Kraaij et al., 2010). 
Excessive ROS, as produced during oxidative stress and inflammation leads to 
increased inflammatory responses and oxidative damage. However, relatively 
low amounts of ROS as produced by macrophages are instrumental in cell 
signaling and can suppress inflammation as shown previously (Gelderman 
et al., 2007;Kraaij et al., 2010;Segal et al., 2010). We have shown an immune-
modulating function of ROS and that in particular anti-inflammatory Mph use 
this function to exert their T cell suppressive properties (Kraaij et al., 2010). 
Others have also shown a ROS-mediated T cell suppression and ROS-mediated 
induction of Treg, as these effects were abrogated when NOX2 was functionally 
inhibited (Efimova et al., 2011). Moreover, it has been shown that myeloid-
derived suppressor cells can also induce Treg via the production of ROS (Lee 
et al., 2011). These data indicate that the production of ROS by certain myeloid 
cells can possibly be of clinical importance. 
Here we demonstrate that IS drugs do exert an effect on the ROS producing 
capacity of the anti-inflammatory Mph2, but, interestingly, has no apparent 








Figure 4: Mph2 differentiated in dex show decreased cytokine response. (A, B, C, D) Allogeneic T cells (150,000) 
were stimulated with anti-CD3/28 Ab in combination with Mph2 differentiated in presence of dex or no drugs, 
and added in a dose-dependent fashion in ratios as depicted on the x-axis. (A) Proliferation, (B) IFN- production, 
and (C) IL-4 production, were determined in the same well for all conditions after 5 days of coculture. A 
representative experiment out of 4 is shown. Depicted are averages and standard deviations of triplicates within 
this experiment. (D) The relative effect of dex treated Mph2 on proliferation, IFN- and IL-4 production at a 1:8 
ratio; mean and SEM of 3-4 experiments. * P<0.05, **P<0.005.
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the capability of anti-inflammatory Mph2 to produce ROS. Intriguing, this 
effect was only observed when IS drugs were present during differentiation 
of monocytes towards Mph, but not when drugs were added to already 
differentiated Mph. This indicates that IS drugs do not negatively influence 
the phenotype and function of anti-inflammatory myeloid cells, which is of 
great importance when considering these cells for cell therapy. In addition, 
dex also increased the ROS producing capacity of DCs, whereas only very 
little ROS production is observed in normal DCs. Dex is known to provide DC 
with tolerogenic properties (Morelli and Thomson, 2007;Stax et al., 2008;van 
Kooten et al., 2011). In earlier studies it was shown that during cultivation in 
dex, DCs are frozen in an immature state that is associated with lower levels 
of pro-inflammatory cytokine production and lower levels of T cell activation 
(Woltman et al., 2000). Additionally these cells also yielded lower donor-
specific T cell responses in a kidney transplantation model in the rat (Stax et al., 
2008). Apparently dex diverts the DC towards an immune modulating cell with 
decreased pro-inflammatory properities, among them is an increase in ROS 
producing capacity which can be an additional immune regulatory mechanism. 
Furthermore, dex increased the T cell suppressive ability of Mph2 with regard to 
IFN-γ and IL-4 production, even though dex did not enhance T cell suppression 
by Mph2. Thus dex further modulates the T cell function, indicating that dex 
indeed aids in augmenting the T cell suppression by Mph2.
Rapamycin, an inhibitor of the mTOR kinase, is clinically used as an 
immunosuppressive drug due to its interference with IL-2 signaling and 
subsequent inhibition of T cell activation, while at the same time enriching for 
Treg (Weichhart and Saemann, 2009). However, in monocytes/macrophages 
mTOR signaling seems to limit the pro-inflammatory response and treatment 
with rapa results in an increased cytokine response, including IL-12, TNF and 
IL-6 (Weichhart et al., 2008). We observed a similar enhanced LPS-induced IL-6 
production upon rapa treatment (data not shown). In contrast IL-6 production 
was inhibited by dex. Interestingly we found that rapa decreased the ROS 
producing capacity of the anti-inflammatory Mph2. This would be in line with 
the hypothesis that ROS acts as a regulatory molecule in Mph2, and that this 
process is counteracted by inhibition of the regulatory mTOR pathway. It has 
been reported previously that rapa increased monocytic NOX2-dependent 
ROS production, but these cells were only treated for a short period, thereby 
not providing the time for functional alterations (Engelbrecht et al., 1994). 
The effect of dex on ROS production by different cell types and in different 
settings has been studied before, with different results. An increase in ROS 
production has been described in dex-treated monocytes stimulated with 
N-formyl-methionine-leucine-phenylalanine (fMLP), whereas suppression was 
seen when stimulated with microbial agents (Zhu and Mrowietz, 2005). In 
addition, an increase in ROS was shown in adipocytes and insulin-producing 
cells after treatment with dex, whose effects could be inhibited with the use of 
ROS scavengers (Houstis et al., 2006;Roma et al., 2009). This has been shown in 
vivo as well, where it was observed that injection of dex induced hypertension 
in a ROS-dependent manner in rats (Hu et al., 2006). In contrast, in PMNs it was 
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shown that short term dex treatment had no effect on p47phox mRNA expression, 
but reduced gp91phox mRNA expression (Amezaga et al., 1992). Other studies 
using the monocytic cell line THP-1 showed that a short treatment with dex 
downregulated gp91phox protein levels (Ahmed et al., 2003), or decreased both 
p47phox and gp91phox RNA expression in THP-1 cells differentiated in IFN-γ and 
TNF-α (Condino-Neto et al., 1998). The pro-inflammatory cytokines IFN-γ and 
TNF-α increased the expression of both p47phox and gp91phox, which was then 
attenuated by the anti-inflammatory dex. Interestingly, CGD patients are also 
treated with IFN-γ, which may have similar effects in patients with some NOX2 
rest function (Segal et al., 2011; Weening et al., 1995).
We here show both in vitro as well as in vivo in a rat model that dex increases 
the ROS producing capacity of circulating monocytes/macrophages. Others 








Figure 5: Dex increases ROS producing capacity and ROS dependent Treg induction in vivo. (A) DA.Ncf1DA/DA 
(DA/DA) rats that express alleles leading to low ROS producing capacity and DA.Ncf1E3/E3 (E3/E3) rats that express 
alleles conferring normal levels of ROS production were injected with 0.15 mg dex or PBS as control at day 0 
and day 4 (arrows) and the capacity to of their peripheral blood monocytes/macrophages to produce ROS was 
followed in time. The relative ROS producing capacity (PBS control on 1 for both groups) after PMA stimulation of 
circulating monocytes/macrophages is shown. (B) ROS producing capacity after PMA stimulation of neutrophils 
at day 5 in dex or PBS treated DA.Ncf1E3/E3 rats. (C) Treg gating strategy on peripheral blood. (D) The percentage 
of FoxP3+ cells amongst CD3+CD4+CD25bright cells in the blood of these rats at day 22. Averages with SEM of 5 
rats per group are shown. *P<0.05.
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dex was administered in the drinking water for 48 hours (Roshol et al., 1995). 
Interestingly, we see our effect only in monocytes/macrophages with normal 
ROS producing capacity, whereas no effect was observed in monocytes/
macrophages with low ROS producing capacity and neutrophils from rats 
with a normal ROS production. The effect of dex may thus, at least partly, be 
mediated via ROS production by monocytes/macrophages. It is possible that 
dex treatment influences the NOX2 complex itself. The gp91phox mRNA level in 
Mph2 was not changed, but p47phox was increased by dex. In DCs an increase 
for both p47phox and gp91phox was observed, although it should be noted that 
these levels were lower in DC compared to Mph2. Since dex apparently does 
not change the NOX2 protein level in Mph2, it is most likely that other levels of 
regulation are involved, including phosphorylation or subcellular localization of 
the NOX2 complex. Even though we cannot directly link the activity of p47phox 
with the increased ROS producing capacity of dex, it is important to note that 
the increased ROS producing capacity by dex in Ncf1E3/E3 rats was not observed 
in the Ncf1DA/DA rats which have a polymorphism in p47phox, thereby suggesting 
a mechanism involving p47phox. 
In conclusion, we show that dex increases the ROS producing capacity of anti-
inflammatory Mph in vitro as well as in vivo. Since Mph2 may be instrumental 
in down-regulating T cell responses via the production of ROS, the addition 
of dex may then amplify this response. Therefore we propose an additional 
mechanism in which dex enhances T cell suppressive capacity of myeloid cells.
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Abstract
Reactive oxygen species (ROS) produced by macrophages have recently been 
shown to have immunosuppressive properties and induce regulatory T cells. 
Here we investigated the ROS producing capacity of well-defined human 
Mph2 subsets and studied the contribution of ROS in the Mph-T cell interaction. 
Mph were generated from monocytes using M-CSF (Mph2), IL-4 (Mph2a), 
or IL-10 (Mph2c). Upon PMA stimulation, Mph2 and Mph2c showed a high 
ROS producing capacity, whereas this was low for Mph2a. Mph2 and Mph2c 
displayed a reduced T cell stimulatory capacity compared to Mph2a. Addition 
of the ROS inhibitor DPI decreased the T cell proliferation and IFN-γ production. 
When testing directly on Mph, DPI dose-dependently decreased the IL-10 and 
IL-12p40 production of CD40L-stimulated Mph2 subsets. In conclusion, the 
ROS producing capacity is different among human Mph type-2 subsets. In all 
cases, DPI suppressed T cell proliferation and cytokine production, indicating a 
ROS-dependent mechanism of T cell activation.
Introduction
Macrophages (Mph) represent a heterogeneous group of myeloid cells, with 
a phenotypic and functional specialization and a high plasticity depending 
on the local cytokine milieu. Mph can be broadly divided into classically 
activated (Mph1) and alternatively activated macrophages (Mph2), with their 
cytokine production profile as an important functional difference [1]. Mph1 
are characterized by production of pro-inflammatory cytokines like TNF-α 
and IL-12, whereas Mph2 produces large amounts of IL-10. In addition, Mph2 
can be distinguished from Mph1 based on their expression of CD163 and 
CD206, although different expression levels have been reported depending 
on the Mph2 subtype [2-5]. For mouse, Mph2 specific markers, like FIZZ1 
and Ym1, have been identified both in vivo and in vitro [6], but establishing 
specific phenotypic markers for human Mph2 is still an ongoing challenge. 
CD163 positive staining on resident tissue macrophages has been found 
dispersed throughout the body, indicating that in vivo Mph represent a Mph2 
phenotype [7]. Placental Mph also display an Mph2-like phenotype, indicated 
by the expression of specific Mph2 markers, and their anti-inflammatory 
phenotype [8;9]. In addition, tumor-associated macrophages (TAMs) also have 
a phenotype and function similar to Mph2: high expression of CD206, poor 
antigen presentation, high IL-10, but low IL-12 production [10].
In vitro, Mph1 can be polarized by IFN-γ, LPS, and/or GM-CSF, thereby 
generating a pro-inflammatory phenotype. In addition, different Mph2 
subsets have been described, depending on the different ways of generation, 
including culture in IL-4/IL-13, immune complexes, or IL-10/TGF-β, generating 
M2a, M2b, M2c respectively [4;11-14]. Recently, we and other have shown that 
also generation of Mph in the presence of M-CSF results in cells (Mph2) with 
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anti-inflammatory properties [4;13;15]. Since M-CSF is present constitutively 
in blood, this suggests that under homeostatic conditions macrophages will 
mostly acquire Mph2 properties [16].
One major characteristic which has been proposed to be different between 
Mph1 and Mph2 is their capacity to produce reactive oxygen species (ROS), 
which has been mostly linked to pro-inflammatory cells [3;12;17;18]. The 
importance of ROS in our immunity is demonstrated in patients with Chronic 
Granulomatous Disease (CGD) who have mutations in various components of 
the phagocytic NADPH oxidase (NOX2) complex, and suffer from recurrent 
infections. However, these patients are also characterized by chronic 
inflammation, increased autoimmunity and a hampered ability to control 
inflammation [19]. These latter findings have also been observed in mouse 
models with defects in NOX2 proteins and were shown to be macrophage 
dependent [20;21]. Recently, we showed that M-CSF differentiated Mph2 have 
a high ROS producing capacity, and were able to suppress T cell responses in 
a ROS-dependent manner [4;15]. 
In the current study we investigated whether there is a difference concerning 
the ROS producing capacity between various well defined human Mph2 
subsets. Moreover, we studied the role of ROS in the Mph-T cell interaction. 
We show that Mph2 subsets display a differential capacity to produce ROS. 
However, the ROS inhibitor DPI inhibited the T cell stimulatory capacity and 
cytokine production by all Mph2 subsets, suggesting involvement of a ROS-
dependent signaling pathway. 
Materials and methods
Cell culture
Monocytes were isolated from buffy coats by CD14+ MACS-bead selection 
(Miltenyi Biotec) [22]. Monocytes were cultured for 7 days in 5 ng/ml M-CSF 
(R&D systems; Mph2), in 15 ng/ml IL-4 (Biosource; Mph2a), or in 15 ng/ml 
IL-10 (ITK; Mph2c). Cells were cultured in RPMI with 10% FCS and penicillin/
streptomycin (RPMI++) in 6 wells plates with 1.5x106 cell per well; medium 
and cytokines were refreshed twice. Macrophages were harvested by gentle 
scraping after short trypsinization. 
ELISA
Macrophages were harvested, replated and stimulated with 200 ng/ml LPS for 
16 hours and subsequently supernatants were collected. In the experiments 
with diphenyleneiodonium (DPI) (Sigma) the cells were cultured for 48 hours in 
the presence of 200 ng/ml LPS or L-CD40L cells [23], thereafter supernatants 
were harvested. In other experiments cells were incubated with 50 U/ml 
Catalase (Sigma) for 48 hours hereafter supernatants were harvested. The IL-6, 
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Flow cytometry
Cell surface molecule expression was assessed by flow cytometry using 
FACSCalibur and BD CellQuest software (BD Biosciences). ROS production was 
determined by staining the cells with 5 µM dihydrorhodamine123 (DHR123) 
for 10 min at 37°C in medium and stimulation with 300 ng/ml phorbol-12-
myristate13-acetate (PMA) for 20 min at 37°C. In certain cases the cells were 
stimulated for 1 hour with DPI before measuring ROS production. Expression 
levels of DC-SIGN (R&D), CD14-PE , CD163, CD86 (all BD Biosciences), and 
HLA-DR (clone B8.11,2; ATCC) with secondary Ab GαM-PE (DAKO) were 
determined. Protein levels of p47phox and gp91phox were determined by 
intracellular staining. The cells were permeabilized, fixed (BD Biosciences), and 
stained with anti-p47phox, anti-gp91phox (Santa Cruz), or an isotype control (BD 
Biosciences) and detected with GαM-PE (DAKO). Cell death was determined 
by incubating the cells with propidium iodide (Invitrogen). 
Figure 1: Mph2a are phenotypically and functionally distinct from Mph2 and Mph2c. (A) Expression levels of 
CD14 (left), CD163 (middle), and CD209 (right) for Mph2, Mph2a, and Mph2c as determined by flow cytometry. 
(B) IL-6 (left), IL-12p40 (middle), and IL-10 (right) production were determined for Mph2, Mph2a and Mph2c after 
16 hours of LPS stimulation by ELISA. Mean and SEM are shown for 4-8 independent experiments. (C) Allogeneic 
T cells (150,000) were stimulated with respectively Mph2, Mph2a, or Mph2c in different ratios as depicted on the 
x-axis. Proliferation (left; * P<0.05 Mph2a vs Mph2 and Mph2c) and IFN-γ production (right; * P<0.05 Mph2a vs 
Mph2 and Mph2c, ^ P<0.05 Mph2a vs Mph2c) were determined after 5 days of coculture. Depicted are averages 
and SEM of 9-10 independent experiments. * P<0.05, ** P<0.01, *** P<0.001.
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Amplex Red Assay
Hydrogen peroxide levels were determined using the Amplex Red assay. Mph2 
subsets were incubated with 12.5 µM Amplex Red (Invitrogen) and 0.5 U/ml 
HRP (Sigma) for 20 min at 37°C. The reaction was measured for fluorescence 
intensity (excitation 530 nm, emission 590 nm) at a cytofluor (Perseptive 
Biosystems). Hydrogen peroxide levels determined in the presence of Cat 








Figure 2: Mph2a have a decreased ROS producing capacity. (A) FACS histograms of DHR123 fluorescence after 
staining of Mph2 (left), Mph2a (middle) and Mph2c (right) to detect ROS production after PMA stimulation (filled 
histogram) compared to the DMSO control. (B) The ratio of ROS production as induced by PMA or in absence 
of stimulation (DMSO; vehicle control) was determined for the Mph2 subsets in paired samples (N=20). (C) Fully 
differentiated day 6 Mph2 were incubated with IL-4 for indicated time points and the ROS production relative to 
untreated Mph2 was determined (N=4). (D) mRNA levels for p47phox (left) and gp91phox (right) as determined by 
qPCR. In every experiment, mRNA expression normalized for GAPDH and determined for Mph2 was put on 1.0 
and Mph2a and Mph2c expression was related to that value. Mean and SEM of 4-9 individual experiments are 
shown. (E) Protein levels for p47phox (left) and gp91phox (right) were determined by flow cytometry after intracellular 
staining. Mean with SEM are shown for 6 individual experiments. * P<0.05, ** P<0.01, *** P<0.001.
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T cell proliferation assay
150.000 total T cells were cocultured with different ratios of allogeneic Mph. 
In some experiments this was done in the presence of Catalase (50 U/ml) or 
DPI (0.02/0.3 µM). In other experiments T cells were activated with 0.25 µg/
ml anti-CD3 and 0.5 µg/ml anti-CD28 (Sanquin) in the presence of different 
concentrations of Cat and DPI. After 5 days supernatants were harvested and 
IFN-γ (Biolegend) levels were determined by ELISA. T cell proliferation was 
measured by adding 0.5 µCi 3H thymidine to the cocultures at day 5 for 16 
hours.
L-CD40L cell activation assay
Mph were cultured in a 2:1 ratio with L-CD40L cells or its control L-Orient for 48 
hours as previously described [23]. Different concentrations of DPI or diluent 
(DMSO) were added to the cultures and supernatants were harvested to detect 
marker expression and cytokine production.  
mRNA isolation and Quantitative PCR
mRNA was isolated using a Qiagen kit. After making cDNA, quantitative 
PCRs were performed on a Bio-Rad Icycler machine using the following 
primers: p47phox (Forward: CCTGACGAGACGGAAGAC; Reverse: 
GGGAAGTAGCCTGTGACG), gp91phox (Forward: TAGTGGGAGCAGGGATTG; 
Reverse: TCAAAGGCATGTGTGTCC). The following GAPDH primers were 
used for normalization: Forward TTCCAGGAGCGAGATCCCT and reverse 
CACCCATGACGAACATGGG.
Statistics 
Results of different independent experiments were averaged and subjected 
to statistical analyses. Significant differences were determined using either the 
Student’s T-test, one-way or two-way ANOVA. 
Results 
Mph2a are phenotypically and functionally distinct from Mph2 
and Mph2c 
Different Mph2 subsets were generated by differentiating monocytes with 
M-CSF, IL-4 or IL-10 towards Mph2, Mph2a, and Mph2c, respectively. Phenotypic 
analysis showed that CD14 and CD163 were highly expressed by both Mph2 
and Mph2c, whereas low CD209 (DC-SIGN) expression was observed (Figure 
1A). The opposite pattern was observed for Mph2a, showing low CD14 and 
CD163, but high CD209 expression (Figure 1A). Functionally, upon LPS 
stimulation Mph2a had a higher IL-6 and IL-12p40 production compared to 
Mph2 and Mph2c (Figure 1B). High IL-10 production was observed for Mph2, 
while Mph2a and Mph2c produced only low amounts (Figure 1B). 
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Next we investigated the T cell stimulatory capacity of the different Mph2 
subsets in an MLR. Mph2a showed a higher T cell stimulatory capacity, especially 
at higher Mph:T cell ratios, with optimal activation at a 1:6 ratio (Figure 1C). 
A more pronounced, but similar result was observed for IFN-γ production. 
Thus Mph2a is both phenotypically and functionally different from Mph2 and 
Mph2c, showing a higher pro-inflammatory cytokine production and stronger 
T cell stimulatory capacity. 
Mph2a have a decreased ROS producing capacity
Although anti-inflammatory Mph2 are usually described as non-ROS producing 
cell [3;17], we recently showed that ROS can be produced by Mph2 and has 
profound immuneregulatory effects [4;15]. Therefore, we investigated the ROS 
producing capacities of the different type 2 Mph as characterized above. In 








Figure 3: DPI decreases T cell proliferation in an MLR. (A) Flow cytometric analysis of the relative ROS producing 
capacity of Mph2, Mph2a, and Mph2c as induced by PMA stimulation in the presence of increasing concentrations 
of DPI. Mean and SEM are depicted from 5 independent experiments. (B) Allogeneic T cells (150,000) were 
stimulated with increasing amounts of Mph2, Mph2a, or Mph2c respectively in the presence of 0.02 or 0.3 μM 
DPI or DMSO as indicated, and proliferation was measured at day 5 of culture. A representative experiment is 
shown (C) Relative proliferation (left) and IFN-γ production (right) (DMSO at 100) is shown for Mph2, Mph2a, 
Mph2c at a ratio of 1:18, and anti-CD3/28-activated T cells in the presence of DPI. Mean and SEM are shown for 
5-6 individual experiments. * P<0.05, ** P<0.01, *** P<0.001.
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ROS producing capacity compared to Mph2 and Mph2c (Figure 2A,B). We 
have shown before that monocyte-derived dendritic cells, differentiated with 
GM-CSF and IL-4, have low ROS producing capacity [15], whereas monocytes 
themselves have a high ROS producing capacity (data not shown). Therefore 
we investigated whether exposure to IL-4 directly affects the ROS producing 
capacity. When IL-4 was added to fully differentiated Mph2, we observed a 
time-dependent decrease in ROS producing capacity (Figure 2C). 
Since Mph2 derived-ROS is produced by the NOX2 complex [15], we 
investigated the expression of two important proteins of the NOX2 complex 
as a possible explanation for the difference in ROS producing capacity. Both 
mRNA and protein expression of p47phox was similar between Mph2 subsets 
(Figure 2D,E). In contrast, the mRNA levels of gp91phox were lower in Mph2a and 
Mph2c compared to Mph2 (Figure 2D). Moreover, Mph2a also has diminished 
gp91phox protein expression compared to Mph2 (Figure 2E). We conclude that 
the IL-4-generated Mph2a have a lower NOX2-mediated ROS production.
DPI decreases T cell proliferation in an MLR 
In view of the immunosuppressive role of ROS, we hypothesized that the 
presence of ROS in Mph2 and Mph2c might contribute to their decreased T 
Figure 4: DPI affects IL-12p40 and IL-10 production of the Mph2 subsets. (A) Percentage living Mph2 in the 
presence of different concentrations of DPI as determined with PI staining by flow cytometry. A representative 
experiment out of 3 is shown. (B) Relative IL-6 production of Mph2 (left) and Mph2a (right) activated with L-CD40L 
cells (L-Orient as control) (L-CD40L DMSO set at 100) in the presence of DPI for 48 hours as determined by ELISA 
(L-CD40L DMSO, average production Mph2 241 pg/ml; Mph2a 315 pg/ml). (C) Relative IL-12p40 production of 
Mph2 (left) and Mph2a (right) (L-CD40L DMSO, average production Mph2 2846 pg/ml; Mph2a 4088 pg/ml). (D) 
Relative IL-10 Mph2 (left) and Mph2a (right) (L-CD40L DMSO, average production Mph2 609 pg/ml; Mph2a 501 
pg/ml). Mean and SEM are shown for 5-6 independent experiments. * P<0.05, ** P<0.01, *** P<0.001.
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cell stimulatory capacity (Figure 1C). To investigate this we used the commonly 
used ROS inhibitor diphenyleneiodonium (DPI), which interacts with the 
C-terminal flavin-binding domain of gp91phox [24]. DPI inhibited the ROS 
production of Mph2, Mph2a, and Mph2c (Figure 3A). At high concentrations 
DPI inhibited proliferation and IFN-γ production by anti-CD3/CD28-activated 
T cells (data not shown). Therefore we used low concentrations of DPI (0.02 
µM and 0.3 µM) to investigate the role of ROS in the T cell stimulatory capacity 
within the MLR. For all three Mph subsets, DPI dose-dependently inhibited the 








Figure 5: Catalase has no effect on T cell proliferation in an MLR. (A) Extracellular hydrogen peroxide levels 
measured as fluorescence intensity (FI) of Mph2, Mph2a, and Mph2c as determined by AmplexRed assay. (B) FI 
of different concentrations of hydrogen peroxide in the presence of different concentrations of Cat as indicated. 
(C) Allogeneic T cells (150,000) were stimulated with anti-CD3/28 in the presence of different concentrations 
of Cat. Proliferation was determined after 5 days of culture. A representative experiment depicting averages 
and SEM of triplicates is shown. Allogeneic T cells (150,000) were stimulated at a ratio of 1:6 with respectively 
Mph2, Mph2a, or Mph2c in the presence of 50 U/ml Cat. (D) Proliferation and (E) IFN-γ production are depicted.
(F) IL-12p40 production of Mph2a after 48 hours incubation in the presence of 50 U/ml Cat as determined by 
ELISA. In all cases mean and SEM are shown of 5-7 independent experiments. * P<0.05, ** P<0.01.
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quantifying the data, it appeared that Mph2a were less sensitive for inhibition, 
and higher concentrations were needed to reach a significant inhibition (Figure 
3C). Similarly in all cases also the IFN-γ production was strongly inhibited by 
DPI. Under these conditions, proliferation and IFN-γ production by T cells 
activated by CD3/CD28 were not affected. These data show that, opposite 
to our hypothesis, ROS production by macrophages is essential for the T cell 
Figure S1: (A) HLA-DR (left) and CD86 (right) expression after 48 hours incubation with DPI for Mph2, Mph2a, 
and Mph2c. (B) Relative IL-6 production of Mph2 (left; average production of 1048 pg/ml) and Mph2a (right; 
average production of 1045 pg/ml) stimulated with LPS (DMSO set at 100) in the presence of DPI for 48 hours 
as determined by ELISA. (C) Relative IL-12p40 production of Mph2 (left; average production of 1010 pg/ml) 
and Mph2a (right; average production of 3351 pg/ml). (D) Relative IL-10 production of Mph2 (left; average 
production of 741 pg/ml) and Mph2a (right; average production of 442 pg/ml). In all cases mean and SEM are 
shown for 3-5 individual experiments. * P<0.05, ** P<0.01, *** P<0.001.
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stimulatory capacity, and cannot explain the reduced T cell stimulation by 
Mph2 and Mph2c.
DPI affects the cytokine production of the Mph2 subsets
We next explored the potential mechanisms how NOX2 might be involved in 
the T cell stimulatory capacity. DPI up to a concentration of 5 µM, showed no 
effect on the viability of Mphs (Figure 4A). The stimulation of T cells by APCs 
requires MHC class ІІ and co-stimulatory molecule activation, as well as cytokine 
production. However, HLA-DR and CD86 expression on the Mph2 subsets were 
not affected by DPI (Supplementary Figure 1A). 
Therefore we investigated the cytokine production of Mph2 subsets activated 
by CD40L to mimic the CD40-CD40L signal between APC-T cell as it occurs 
during the MLR reaction. IL-6 production by Mph2 and Mph2a was increased 
upon stimulation with L-CD40L cells, but no effect of DPI was observed (Figure 
4B). In contrast, the strongly increased production of IL-12p40 (Figure 4C) and 
IL-10 (Figure 4D), was dose-dependently inhibited by DPI. In LPS-stimulated 
Mph2 and Mph2a, the IL-6, IL-12p40, and IL-10 production was suppressed 
by DPI (Supplementary Figure 1B,C,D). Similar trends were observed with the 
cytokine production of Mph2c (data not shown).
Catalase has no effect on T cell proliferation in an MLR 
Although we identified an important role for ROS in Mphs for their T 
cell stimulatory capacity, this does not clarify the molecular mechanism. 
Hydrogen peroxide, a product of ROS generation is a known for its role as 
second messenger, its relatively long half-life and its ability to move through 
membranes [25;26]. Using the Amplex Red assay, which detects extracellular 
hydrogen peroxide, similar basal levels of extracellular hydrogen peroxide 
were observed for Mph2, Mph2a, and Mph2c (Figure 5A). The high signal 
in Mph2a indicates that apart from NOX2, also other sources produce ROS 
resulting in hydrogen peroxide. Catalase (Cat), a specific hydrogen peroxide-









Figure S2: Allogeneic T cells (150,000) were stimulated with respectively Mph2 (left), Mph2a (middle), or Mph2c 
(right) in the presence of 50 U/ml Cat in different ratios as depicted on the x-axis. A representative experiment is 
shown. Depicted are averages and SEM of triplicates within this experiment.
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Neither the proliferation of anti-CD3/CD28-activated T cells (Figure 5C), 
nor the T cell proliferation induced by Mph2, Mph2a, or Mph2c (Figure 5D, 
Supplementary Figure 2) was affected by the addition of 50 U/ml of Cat. In 
addition, no effect on the IFN-γ production induced by Mph2 or Mph2c was 
observed (Figure 5E). However, when using Mph2a as T cell activator, addition 
of Cat strongly increased the IFN-γ production (Figure 5E). In line with this, 
when tested directly on Mph2a, Cat did also increase the IL-12p40 production 
(Figure 5F). Thus whereas hydrogen peroxide seems not involved in T cell 
proliferation, it does affect the quality of the T cell response induced by Mph2a.
Discussion 
In this study we showed a difference in ROS producing capacity among human 
Mph2 subsets; Mph2 and Mph2c have a higher ROS producing capacity 
compared to Mph2a. In addition, we observed decreased T cell proliferation 
with DPI for all Mph2 subsets, indicating that the ROS producing capacity of 
Mph2 and Mph2c is not directly associated with their reduced T cell stimulatory 
capacity. This decreased T cell proliferation could be explained by decreased 
IL-10 and IL-12p40 production in the presence of DPI. These data suggests a 
ROS-dependent mechanism of T cell activation via the cytokine production. 
In vitro, monocytes can be differentiated in functionally different Mph2 subsets. 
We found that Mph2 and Mph2c, differentiated by M-CSF and IL-10 respectively, 
are both phenotypically and functionally similar. The expression of markers 
was in agreement with another study demonstrating similarity between M-CSF 
and IL-10 polarized Mph, but a difference with IL-4 [2]. Traditionally, the ROS 
producing capacity has been associated with pro-inflammatory type-1 Mph, 
but less with anti-inflammatory Mph2. However, we showed before that the 
M-CSF differentiated Mph2 are capable of producing ROS [4;15]. Therefore 
we investigated the ROS-producing capacity of different Mph2 subsets. 
Importantly, Mph2a, generated in the presence of IL-4, produce lower levels of 
ROS after PMA stimulation compared with Mph2 and Mph2c. This is in line with 
the observation that also monocyte-derived dendritic cells, generated in the 
presence of IL-4 and GM-CSF lack the ROS producing capacity [15]. We showed 
that Mph2a have lower gp91phox protein expression, an effect previously shown 
in IL-4-treated porcine and mouse Mph [27;28]. In addition we showed that 
IL-4 directly affects the ROS producing capacity, also in fully polarized Mph2 
cells. Finally also in patients treated with IL-4 in vivo, a reduced capacity of 
monocytes to produce superoxide was observed [29]. Therefore, IL-4 signaling 
seems a key factor in myeloid cells to regulate their ROS producing capacity.
T cell proliferation was not affected in the presence of Cat, although the IFN-γ 
production was increased with Mph2a-stimulated T cells, indicating that 
hydrogen peroxide decreases the T cell activation capacity of Mph2a. This 
might be explained by the increase in IL-12p40 levels of Mph2a when Cat is 
present. In agreement, hydrogen peroxide inhibited the IL-12p40 induction in 
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murine Mph [30]. 
In contrast, DPI did affect the T cell activation, as shown by the suppressed 
proliferation and IFN-γ production in an MLR. There appears to be a 
discrepancy between the concentrations of DPI required to inhibit ROS 
production by the Mph and the T cell suppression by DPI. However, we did 
observe a trend with decreased ROS production by the Mph also with low 
concentrations of DPI. It should be noted that the measurement of ROS is a 
very short term experiment, whereas T cell proliferation concerns a 5 day assay. 
Attempt to monitor generation of ROS over longer periods was hampered 
by an increase of background staining using the ROS indicator DHR (data not 
shown). Moreover, DPI is not exclusive for the inhibition of NOX2, and is also 
able to inhibit nitric oxide synthase, xanthine oxidase or cytochrome P450 
reductase [31]. This might explain the observation that Mph2a are significantly 
affected by DPI, even though they are very low in NOX2 expression. DPI has 
been shown to decrease the proliferation of different cell types both in vitro 
as in vivo [32-34]. In addition, T cell proliferation was decreased in response to 
antigen presentation in the presence of ROS inhibitors including DPI, whereas 
no effect was observed with Cat [35]. ROS are thus pivotal for T cell activation. 
This was also shown by experiments with an anti-oxidant, where decreased 
proliferation and IFN-γ production was observed, whereas a deficient ROS 
scavenger increased proliferation [36-38]. 
We showed that DPI diminished the IL-10 and IL-12p40 production of the 
Mph2 subsets, but showed no effect on IL-6 production. Thus although we 
observed a ROS-dependent component for the cytokine production, not all 
cytokines have the same dependence with regard to their production. The pro-
inflammatory IL-12p40 is a known T cell activator, whereas the anti-inflammatory 
IL-10 diminishes the production of inflammatory mediators and favors Th2 T 
cell development [39;40]. DPI had no effect on the pro-inflammatory cytokine 
production, including IL-12, with LPS-stimulated dendritic cells [41]. However, 
mouse Mph stimulated with LPS did show decreased pro- and anti-inflammatory 
cytokine production with DPI [42], which we observed as well. Interestingly, 
in CGD patients it has been shown that ROS negatively regulates cytokine 
production during infection, indicating deregulated cytokine production due 
to dysfunctional NOX2 [43;44].
Conclusions 
In conclusion, we here showed that the ROS producing capacity is different 
for different Mph2 subsets; Mph2 and Mph2c have a higher ROS producing 
capacity compared to Mph2a, which is most likely related to a reduced gp91phox 
protein expression. The difference in T cell stimulatory capacity of Mph2 subsets 
is not directly linked with their differential ROS producing capacity. In contrast, 
DPI inhibited T cell proliferation, possibly through decreasing the cytokine 
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Abstract
We previously showed that anti-inflammatory Mph (Mph2) can both in vitro and 
in vivo induce regulatory T cells (Tregs) in a reactive oxygen species (ROS)-
dependent fashion. As influx of Mph is an important characteristic of chronic 
inflammatory responses, we investigated the impact of NOX2-mediated ROS 
production by recipient cells in an experimental model of chronic allograft 
inflammation. We used a kidney transplantation (Tx) model with Lewis (Lew) 
rats as donor and congenic DA.Ncf1DA/DA (low ROS) and DA.Ncf1E3/E3 (normal 
ROS) rats as recipients. At day 7 the contralateral kidney was removed, and 
the animals were sacrificed four weeks after Tx. Renal function and injury 
was monitored in serum and urine and the composition of the infiltrate was 
analyzed by immunohistochemistry. Four weeks after Tx, large leukocyte 
clusters were observed in the allograft, in which signs of ROS production could 
be demonstrated. These clusters showed no difference regarding composition 
of myeloid cells or the number of FoxP3 positive cells. However, T cell infiltrate 
was significantly reduced in the DA.Ncf1E3/E3 recipients having normal ROS 
production. Therefore, this study suggests a regulatory effect of ROS on T cell 
infiltration, but no effect on other inflammatory cells in the allograft.
Introduction 
Loss of renal function will ultimately result in the need for a renal transplantation. 
Despite significant improvement, especially in the early post-transplantation 
period, the occurrence of allograft rejection remains a problem, which negatively 
affects the function and survival of transplanted organs. Allograft rejection is 
characterized by the influx of recipient immune and inflammatory cells in the 
transplanted organ [1;2]. Although initial attention focused on T cell infiltrates, it 
has become clear that also other cells, including B cells, macrophages, dendritic 
cells are part of this infiltrate. However, not all infiltrating cells actively contribute 
to the rejection process, and there is accumulating evidence that some of these 
cells have regulatory functions [3]. Macrophages appear in different subsets 
like the pro-inflammatory Mph (Mph1) which maintain inflammation, and the 
anti-inflammatory Mph (Mph2) that will clear up cell debris and repair the tissue 
[4]. Regulatory T cells (Tregs) can also be part of the infiltrate, and have been 
considered a protective biomarker of graft outcome [5-7]. Therefore, it is of 
great importance to characterize cellular infiltrates and the local inflammatory 
conditions, since these will contribute to the composition of the infiltrate within 
the graft. 
The inflammatory response at time of rejection is characterized by the presence 
of reactive oxygen species (ROS), which are generated amongst others by 
the Mph [8;9]. Next to oxidative stress, also a role for reactive oxygen species 
(ROS) in immune regulation has been observed [10;11]. Recently we showed 
that ROS produced by type 2 Mph contribute to the generation of Tregs [12]. 
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Mph from chronic granulomatous disease (CGD) patients, who have a deficient 
ROS production due to mutations in the phagocytic NADPH oxidase (NOX2) 
complex, were shown to be less efficient in the induction of Tregs. Considering 
that CGD patients are characterized by chronic inflammation, these findings 
point towards a role for ROS in dampening inflammation. In line with this, rats 
and mice with a decreased ROS production have increased T cell activation 
and more severe arthritis, which, in the mouse, was shown to be dependent on 
the ROS producing capacity of Mph [13;14]. 
Here we studied the impact of NOX2-mediated ROS production by recipient 
cells on the inflammatory response in the transplanted kidney. For this we 
used the model of Lewis-to-DA kidney transplantation, resulting in a model of 
chronic inflammation. As recipients we used the congenic rat strains DA.Ncf1DA/
DA and DA.Ncf1E3/E3genotypes, which only differ in their phagocytic NOX2-
derived ROS-producing capacity. In this way, we were able to investigate the 
role of ROS produced by infiltrating inflammatory cells, in chronically inflamed 
kidneys. When sacrificed at 4 weeks, we observed a decreased T cell infiltration 
in grafts derived from recipients with a normal ROS production (DA.Ncf1E3/E3), 
compared with the congenic DA.Ncf1DA/DA recipients. 
Objective
To study the impact of NOX2-mediated ROS production by infiltrating cells on 
the inflammatory response in the transplanted kidney.
Materials and Methods
Animals 
Littermates (DA.Ncf1DA/DA and DA.Ncf1E3/E3) were obtained by intercrossing F1 
animals from a DA (Harlan, Horst, The Netherlands) x DA.Ncf1E3/E3 cross (DA.
Ncf1E3/E3 founders originating from Medical Inflammation Research, Karolinska 
Institute, Stockholm, Sweden) [15]. Lewis rats were purchased from Harlan 
(Horst, The Netherlands). The animals were housed in IVC cages and had free 
access to water and standard rat chow. Animal care and experimentation were 
performed in accordance with the Dutch law and the local committee of animal 
experiments of the Leiden University Medical Center.
Kidney transplantation model
Lewis rats were used as donors and DA.Ncf1E3/E3 (N=5) and DA.Ncf1DA/
DA (N=5) rats (190–350 g) were used as recipients. Kidney transplantations 
were performed under isoflurane anesthesia and 0.02 mg/kg buprenophine 
(Temgesic®, Schering-Plough). The left kidney from the donor was perfused 
using cold ringer (Fresenius Kabi) with 400 U/ml Heparin (LEO, Pharma BV) 
and kept on ice. The left kidney from the recipient was removed and the 
donor kidney was transplanted in the abdominal cavity from the recipient. The 
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recipient aorta and vena cava using running sutures. The donor urether was 
anastomosed end-to-end to the urether of the recipient using lose stitches. 
Postoperatively, 10 mg/kg of cyclosporine (Sandimmune®, Novartis) was given 
daily s.c. and provided up till day 7. Seven days after Tx the contralateral kidney 
was removed. Blood samples were collected at several time points after Tx by tail 
vein puncture. The rats were twice a week placed in metabolic cages to collect 
urine samples. The animals were sacrificed four weeks after Tx. Creatinine and 
urea in serum samples were measured using standard autoanalyzer methods 
by our hospital diagnostic services. In addition, rocket immuno-electrophoresis 
(protocol modified from [16]) was used to quantify albumin levels in urine. 
Immunohistochemistry
Snap frozen rat kidney sections (4 μm) were air dried and acetone fixed. Sections 
were stained for OX-42 (anti-CD11b/c, kindly provided by Dr. P. Kuppen, 
LUMC, Leiden)), ED-1 (anti-CD68; kindly provided by Dr. C.D. Dijkstra, VU, 
Amsterdam), ED-2 (anti-CD163), R73 (anti-TCR; both kindly provided by Dr. E. 
de Heer, LUMC, Leiden), and CD45 (BD Biosciences), followed by horseradish 
peroxidase (HRP)-conjugated goat anti-mouse (Jackson). Goat anti-rat KIM-
1 (TIM-1; R&D) staining was assessed by HRP-conjugated rabbit anti-goat 
(DAKO) as secondary antibody. In addition, the sections were incubated with 
Tyramide-fluorescein isothiocyanate (FITC). FoxP3 (eBioscience) staining was 
followed by secondary rabbit anti-fluorescein HRP antibody (Abcam). All 
stainings were visualized by 3,3’-Diaminobenzidine tetrahydrochloride hydrate 
(DAB, Sigma), followed by nuclear counterstaining with Mayer’s hematoxylin 
(Merck). Quantification of immunohistochemistry was performed by assessing 
10 consecutive fields on each section. Using image J software, the positive area 
in each image (expressed in area fraction) was quantified, except for the FoxP3 
staining where analysis was performed by counting the number of positive 
cells. 
Immunofluorescence
Snap frozen rat kidney sections (10 μm) were air dried. Sections were stained 
with 10 μM dihydroethidium (DHE; Invitrogen) for 30 min at 37°C in the dark. 
After washing the sections were incubated with 1.6 μM Hoechst (Invitrogen) 
for 1 min. Quantification was performed by assessing 15 consecutive fields on 
each section. The positivity of the staining was semi-quantified by assigning 
1 (weak), 2 (positive), or 3 (strong) to each field. The average of all fields was 
takes as measurement of positivity per section.
Statistical analysis
All data were presented as mean ± standard error of the mean (SEM) and 
subjected to statistical analysis with one- or two-way ANOVA and the Mann-
Whitney U-test using GraphPad Prism software. A value of p<0.05 was 
considered statistically significant. 
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Results 
Dysfunctional and damaged kidney four weeks after Tx
In an experimental rat model we transplanted Lewis kidneys into either a 
DA.Ncf1DA/DA (low ROS) or DA.Ncf1E3/E3 (normal ROS) recipient (Fig. 1A). To 
assess renal function, we measured serum creatinine and urea levels and 
observed that both slightly increased at day 6/7 after Tx, but showed a steep 
increase following removal of the remaining native kidney (Fig. 1 B,C). Until 
sacrifice at week 4, a descending trend was observed with creatinine, but 
urea levels remained significantly elevated compared with the pretransplant 
situation. For both parameters, there was no difference between DA.Ncf1DA/DA 
and DA.Ncf1E3/E3 recipients.
Albumin levels in urine were measured as a sign of injury and were significantly 
increased four weeks after Tx, but no difference was observed between 
DA.Ncf1DA/DA and DA.Ncf1E3/E3 recipients (Fig. 1D). It should be noted that the 
albuminuria in this model is low compared to other strain combinations, where 








Figure 1: The ROS producing capacity of recipients does not affect the injury of chronically inflamed transplanted 
kidneys. (A) Experimental model with donor Lewis kidney transplanted into either DA.Ncf1DA/DA (DA) or DA.Ncf1E3/
E3 (E3) rats. Creatinine (B) and urea (C) levels measured in serum from DA rats (N=5) and E3 rats (N=5) at different 
time points after Tx. * p<0.05 compared to d0 for DA, ^ p<0.05 compared to d0 for E3. (D) Albumin levels 
measured in urine and correlated with urine out-put before, at one week and four weeks after Tx. (E) KIM-1 
staining in kidney tissue of control kidney (d0) and four weeks after Tx (4wk). (F) Analysis of KIM-1 staining in 
cortex at d0 and 4wk. * p<0.05, ** p<0.01, *** p<0.001.
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four weeks after Tx was confirmed by strong expression of the tubular the injury 
marker KIM-1, but again no difference was observed between DA.Ncf1DA/DA 
and DA.Ncf1E3/E3 recipients (Fig. 1E,F). 
Leukocyte clusters and ROS present in infiltrate
We next investigated the number of infiltrating cells by staining with the 
leukocyte marker CD45. In the cortex of control kidneys, small numbers of 
CD45 positive cells were observed located in the peritubular space, most likely 
representing resident myeloid cells. In contrast, four weeks after Tx the cortex 
was characterized by a strong increase of CD45 positive cells, observed in large 
leukocyte clusters (Fig. 2A). Both in distribution and quantity, no difference was 
observed between DA.Ncf1DA/DA and DA.Ncf1E3/E3 recipients. 
To monitor the contribution of ROS in the graft inflammation, we stained the 
tissue with the ROS marker dihydroethidium (DHE). DHE staining was observed, 
and most prominently in the leukocyte clusters as indicated by the high cell 
density observed with Hoechst staining, although there was no difference 
Figure 2: Chronically inflamed kidneys are characterized by leukocyte clusters and presence of ROS. (A) 
Representative picture from CD45 staining for both a DA and E3 rat at d0 and 4wk (left). Digital image analysis of 
CD45 staining in of the cortex at d0 and 4wk (right). (B) DHE (upper) and Hoechst (lower) staining of kidney tissue 
from a representative DA and E3 rat at 4wk (left), and semi-quantative analysis of DHE staining at 4wk (right).* 
p<0.05, **p <0.01, *** p<0.001.
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between the rats (Fig. 2B). 
Similar composition of myeloid cell populations
As Mph have an important role in graft rejection [4] and are a major cell type 
expressing NOX2, we investigated the presence of myeloid cells in the kidney 
tissue. A high number of OX42 (CD11b/c) positive cells were seen distributed 
throughout the entire cortex (Fig. 3A). ED-1 (CD68) positive Mph were 
observed both in leukocyte clusters and the peritubular area, whereas ED-2 
(CD163) positive Mph, most likely representing Mph2, were mostly located 
in the leukocyte clusters (Fig. 3B,C). However, the quantity of ED1 and ED2 
positive cells was lower compared with the OX42 staining. 
We also observed OX42 and ED1 positive cells in the glomeruli (indicated by 
arrows), which has been shown before [19]. No difference in DA.Ncf1E3/E3 and 
DA.Ncf1DA/DA rats was shown regarding the number of myeloid cells, although a 
trend towards higher numbers of ED2 positive Mph was observed in recipients 
with normal ROS-producing cells.
Decreased T cell infiltrate with ROS-producing cells
T cells are an essential cell involved in graft rejection [2]. Therefore we stained 








Figure 3: The ROS producing capacity of recipients does not affect the composition of myeloid cell populations. 
(A) OX42, (B) ED-1, (C) and ED-2 staining in the cortex at d0 and 4wk after Tx. On the left side a representative 
picture of the cortex at 4wk from both a DA and E3 rat, and quantification of positive area fraction on the tissue 
on the right side. Arrows indicate positive staining in glomeruli.
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were mostly observed in the leukocyte clusters throughout the cortex, but 
some positive cells were also located in the interstitium (Fig. 4A). The number 
of T cells was significantly lower in DA.Ncf1E3/E3 rats compared to DA.Ncf1DA/DA 
rats (Fig. 4A). 
Since the presence of Tregs can be beneficial for graft outcome [5], we 
investigated the presence of these cells in the kidney tissue. We observed FoxP3 
staining especially in the leukocyte clusters in the cortex, with a trend towards 
lower numbers observed in DA.Ncf1E3/E3 recipients compared to DA.Ncf1DA/
DA rats (Fig. 4B). In view of the reduced T cell infiltrate, the relative amount of 
FoxP3 positive cells (ratio FoxP3: R73 cells) appeared higher in DA.Ncf1E3/E3 rats 
(43 positive cells/ 5 % positive area fraction) compared to DA.Ncf1DA/DA rats (22 
positive cells/ 5 % positive area fraction).
Discussion 
In this study we investigated the contribution of NOX2-derived ROS in a 
model of chronic renal inflammation. Lewis rat kidneys were transplanted into 
recipients with either normal or reduced NOX2-derived ROS, making use of 
the congenic DA rat strain DA.Ncf1E3/E3 and DA.Ncf1DA/DA. Four weeks after Tx, 
the allografts were still dysfunctional and damage to the kidney tissue was 
observed. Moreover, large leukocyte clusters were observed in the kidney, 
characterized by CD45 and CD11b/c expression. For these parameters, there 
was no difference between DA.Ncf1E3/E3 and DA.Ncf1DA/DA recipients. However, 
a decreased number of T cells infiltrated the Tx kidney when recipients had a 
Figure 4: Decreased T cell infiltrate in recipients with a normal ROS-producing capacity. (A) A representative 
picture of the cortex 4wk after Tx (left) and analysis of R73 staining at d0 and 4wk (right). (B) FoxP3 positive cells 
observed in the cortex at d0 and 4wk after Tx. On the left side a representative picture of the cortex at 4wk from 
a DA and E3 rat, and quantification of the tissue on the right side. * p<0.05
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normal ROS producing capacity. 
The transplant model using DA rats as donor and Lewis rats as recipient has 
been more widely described in the literature [17;20]. In this study we wanted 
to specifically address the contribution of ROS by infiltrating inflammatory 
cells. Therefore we used the congenic DA rats as recipients. We observed 
ROS staining in the kidney tissue, especially in the leukocyte clusters. Making 
use of DHE staining, we observed that also DA.Ncf1DA/DA rats still have ROS 
producing capacity [12;21], indicating that next to NOX2, also other sources 
of ROS are present. ROS produced during oxidative stress (high levels) has 
been implicated in chronic kidney diseases or kidney Tx in a negative way 
[22;23]. In contrast, it has been shown that ROS produced in the immunological 
synapse or produced in lower amounts can inhibit T cell activation and has 
been indicated in various signaling pathways as well [24-27].
Mph2 have been shown to induce Tregs via the production of ROS [12]. In 
the current experiments we found no difference in absolute numbers of FoxP3 
positive cells in the cortex of transplanted kidneys between DA.Ncf1DA/DA and 
DA.Ncf1E3/E3 recipients. However, the reduction in Tregs was not as prominent 
as the reduction in total T cells. Therefore it is tempting to speculate that in 
DA.Ncf1E3/E3 recipients the relative amount of FoxP3 positive cells was higher, 
thereby tilting the balance towards more regulation. This relative increase may 
be important since it has been assumed that the ratio between effector T cells 
and Tregs is a main determinant in allograft outcome [28]. In vitro, Tregs can 
steer monocyte differentiation towards CD163 positive Mph [29], whereas 
in vivo Tregs expansion increased the number of CD163 positive Mph in the 
infiltrate and decreased pro-inflammatory cytokine production [30]. This further 
indicates that Tregs might exert an immune regulatory role on the infiltrating 
cells [31]. However, in the current study this altered balance did not affect any 
of the other inflammatory, injury or functional markers.
When investigating the renal tissue for different myeloid cells, we observed 
OX42 staining throughout the entire cortex located both in the leukocyte 
clusters and between the tubuli. There was considerably less ED1 and ED2 
staining in the cortex compared with OX42. This might suggest that apart 
from Mph also granulocytes (which abundantly express OX42) were present 
in the kidney tissue four weeks after Tx. However, the presence of neutrophils 
at this late stage after Tx is unlikely, although a constant influx of these cells 
due to chronic inflammation is possible. An alternative explanation is that 
OX42 identifies another myeloid population not recognized by ED1 or ED2, 
or that the OX42 expression is higher and therefore more easily detected 
in immunohistochemistry. Similarly, the abundant expression of OX42 can 
explain why reduced amount of T cell infiltrate (as shown by R73 staining) was 
not reflected by a difference in CD45 staining.
ED1 is considered to be a general Mph marker, whereas ED2 is more specific 
for Mph2. Since, compared to ED1, there was less ED2 staining present in the 
infiltrate, it is likely that also Mph1 were present. This indicates that both pro-
inflammatory mechanisms and tissue repair were simultaneously taking place 
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and DA.Ncf1DA/DA rats, this suggests that the ROS producing capacity of the 
recipient’s immune cells is not involved in the active process of Mph recruitment 
and function after Tx. However a trend towards more Mph2 was observed in 
the grafts from DA.Ncf1E3/E3 recipients. The presence of the diverse immune 
cells in the lymphoid clusters would allow interactions between these cells 
and therefore also allow for the possibility of ROS signaling within the graft. 
Nevertheless, diminished numbers of R73 positive T cells were observed in 
the cortex of the Lew kidney with DA.Ncf1E3/E3 rats as recipients. By performing 
the renal transplantation and analyzing the tissue of this chronically inflamed 
allograft (with infiltrating macrophages having a difference in ROS producing 
capacity), we hypothesized to pick up differences in the ‘local’ inflammatory 
response (ie in the graft). However, we cannot exclude that part of the difference 
we ultimately found has its origin at other locations (like in the lymphoid 
organs). This will be the place where most T cell activation will be initiated, 
and also here signaling through ROS might take place. Since these molecules 
only act on a short distance it could be hypothesized that the immunological 
synapse could be important for this process. The reduced T cell infiltrate could 
potentially hint towards an immunosuppressive role of NOX2-derived ROS. In 
a collagen-induced arthritis model Mph-derived ROS was clearly shown to be 
beneficial in suppressing T cell responses [13]. It most likely that the subtle 
ROS producing capacity by Mph in our model was insufficient to overcome the 
high inflammatory state in the kidney after Tx, which only showed a decreased 
T cell infiltrate. Due to the nature of our model, we believe that the amount 
of ROS produced here by Mph was insufficient to have an impact on the 
inflammatory response in the allograft. We recently showed that inhibition of 
ROS can under some conditions also suppress T cell proliferation [32]. In that 
study we used a human in vitro model of monocyte-derived macrophages and 
used the inhibitor DPI for blocking ROS-mediated effects. Unfortunately, DPI 
is not specific for NOX2, and therefore this can explain the inhibitory effects 
of DPI on T cell activation. In the current study the difference is based on a 
genetic polymorphism in one of the NOX2 gene, and therefore can specifically 
address differences in NOX2-mediated ROS. A partially protective role of ROS 
under such conditions is in line with various auto-immune diseases where Mph-
derived ROS has been shown to be essential for protection [13;14].   
In conclusion, in the Lew-to-DA renal Tx model we observed leukocyte clusters 
four weeks after Tx. In these clusters the presence of myeloid cells and 
FoxP3 positive Tregs were observed, but no difference was shown between 
DA.Ncf1E3/E3 and DA.Ncf1DA/DA rats. Although a decreased number of infiltrating 
T cells was shown in allografts of DA.Ncf1E3/E3 recipients having a normal ROS-
producing capacity, in this experimental model no effect was observed on 
other inflammatory cells or signs of injury. 
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Discussion
In recent years the view on the biological role of reactive oxygen species (ROS) 
has dramatically changed and a functional role for macrophage (Mph)-derived 
ROS in T cell activation and auto-immunity has been documented. Rats with 
a reduced ROS producing capacity showed an increased susceptibility to 
pristane-induced arthritis, which was mediated in a T cell-dependent fashion 
(1). In addition, mice expressing functional NOX2 protein p47phox only in their 
Mph were protected against disease compared to mice with fully functional 
p47phox in an arthritis model (2). Finally, T cell activation is inhibited by hydrogen 
peroxide and ROS have been implicated to play a role in the process of antigen 
presentation (3-5). Altogether, since especially Mph-derived ROS seems to 
play an important role, in the current thesis we aimed to explore this further by 
investigating different Mph subsets and the immune modulating potential of 
Mph-derived ROS. This chapter summarizes and discusses the contribution of 
the research described in this thesis in order to understand the role of ROS in 
the Mph-T cell interaction. 
ROS producing capacity of macrophages
The NOX2-derived ROS producing capacity is different between human Mph 
subsets, showing a high ROS producing capacity with pro-inflammatory Mph1, 
whereas most literature suggested that the anti-inflammatory Mph2 has little 
to no ROS producing capacity (6,7). Since we were interested in Mph-derived 
ROS, gaining knowledge about the ROS producing potential of these different 
Mph subsets would be essential. Comparing GM-CSF differentiated Mph1 with 
M-CSF differentiated Mph2 showed opposite results, with little ROS producing 
capacity of Mph1 and high ROS production for Mph2 (Chapter 3). 
Mph2 display a high plasticity and can undergo phenotypic and functional 
changes due to the surrounding milieu (7,8). We therefore wanted to investigate 
certain Mph2 subsets in more detail. The most commonly described Mph2 
in literature are Mph2a, which are differentiated with either IL-4 or IL-13. In 
addition, Mph2c are a well-known Mph2 subset and are differentiated with IL-
10 or glucocorticoids. When comparing the phenotype of three different Mph2 
subsets, namely M-CSF differentiated Mph2, Mph2a, and Mph2c, it is striking 
that Mph2 and Mph2c demonstrate a similar phenotype, whereas Mph2a are 
clearly distinct (Chapter 4 and Table 1). The IL-4 differentiated Mph2a drives 
Th2 immune responses, predominantly mediated via STAT6 signaling, whereas 
Mph2c requires STAT3 signaling, which could in part explain the difference 
(9,10). Thus although they are all named anti-inflammatory Mph, phenotypically 
and functionally these Mph2 subsets are different. We showed this in vitro, 
where we observed differences in marker expression and cytokine production, 
and this was also observed in vivo by others (11,12). 
As we showed that M-CSF-differentiated Mph2 had a high NOX2-derived ROS 
producing capacity, which is in contrast with the general opinion, we wanted to 
compare this Mph2 with Mph2a and Mph2c with regard to their ROS producing 
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capacity (Chapter 4). Mph2a do not produce NOX2-derived ROS upon PMA 
stimulation, which is indeed in agreement with literature. In contrast Mph2c did 
show ROS-producing capacity, clearly demonstrating the functional diversity of 
diverse Mph2 subsets. Thus in addition of different expression of cell surface 
markers or cytokine production, the ROS producing capacity is also different 
among Mph2, Mph2a, and Mph2c. This indicates that ROS will most likely 
have different functions within the Mph subsets, related to the various effects 
observed on the immune system, and that subsets should be well described 
and characterized before results can be extrapolated.  
Effect of immunosuppressive drugs on ROS 
Immunosuppressive drugs (IS drugs) are commonly given to prevent T cell 
activation and graft rejection. When considering the side-effects of these drugs, 
developing an alternative therapy is essential. Mph2 have the potential to be 
used as cellular therapy, since they may be instrumental in diminishing T cell 
responses in autoimmunity or preventing allograft rejection in transplantation. 
Currently, cellular therapy with Mph has already been performed. Two patients 
required low-dose immunosuppressive therapy to preserve their grafts from 
rejection, after they received a transfusion with regulatory Mph a week prior 
to their kidney transplantation (13). In protocols where regulatory Mph will be 
used as cellular therapy, this will most likely be in combination with the current 
therapies therefore the effects observed can be potentially of significance. 
However, the IS drugs may affect the immunosuppressive function of the 
Mph2 administered and specifically the ROS producing capacity of Mph may 
be effected. Therefore we investigated in Chapter 3 the effect of IS drugs 
on the ROS-producing capacity of Mph2. Interestingly, we observed that IS 








Table 1: Characteristics of Mph2, Mph2a, and Mph2c regarding markers, cytokines, ROS producing capacity and 
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Mph, which is important when considering Mph2 for cell therapy. The ROS-
producing capacity of Mph2 was augmented by a number of these drugs 
when present during differentiation, indicating that the drugs only influence 
the NOX2 complex as long as monocytes are differentiating into mature Mph2. 
Dexamethasone, which is experimentally one of the strongest and most widely 
used corticosteroid, was one of the IS drugs shown to increase the ROS-
producing capacity of Mph2. In line with this, it was shown that dexamethasone 
could upregulate NOX2 proteins and in vivo increased ROS production was 
demonstrated (14,15). In addition, dendritic cells cultured in dexamethasone 
were frozen in an immature state associated with lower levels of T cell activation 
(16). Dendritic cells were shown to have a very low ROS production in vitro, 
but with the addition of dexamethasone, the ROS producing capabilities of 
dendritic cells were strongly increased (Chapter 3). In summary, in Chapter 3 
we describe an additional anti-inflammatory mechanism of dexamethasone, 
since dexamethasone amplified the down-regulation of T cell responses via the 
production of ROS in Mph2.
 
ROS in T cell activation
A role for ROS in activating T cells was previously shown in a rat model of 
pristane-induced arthritis (1). Suppressed T cell activation by ROS was also 
demonstrated for granulocyte-derived hydrogen peroxide and through the 
effect of catalase on lymphocytes (4,5). Therefore we wanted to investigate the 
role of human Mph-derived ROS on T cell activation (Chapter 4). Interestingly, 
differences in the T cell-stimulatory capacity by Mph2, Mph2a, and Mph2c 
were observed, which was inversely correlated with their ROS-producing 
capacity. Therefore we hypothesized that the ROS-producing capacity of Mph2 
could be functionally important with regards to T cell activation. However, in 
contrast to this hypothesis, T cell activation by Mph2a did demonstrate ROS 
dependency, as T cell activation by Mph2a was inhibited by the ROS inhibitor 
DPI, even when we could not demonstrate any NOX2-derived ROS by Mph2a 
upon stimulation. This indicates that apart from ROS derived from NOX2, ROS 
are also being produced elsewhere in the Mph, although Mph rely primarily 
on NOX2 for ROS production (17). Since DPI not only inhibits NOX2, but also 
the other NOX, nitric oxide synthase, xanthine oxidase or cytochrome P450 
reductase, this suggests involvement of ROS from above mentioned sources in 
T cell activation (18). It was recently shown that mitochondrial ROS are required 
for T cell activation and the subsequent IL-2 induction (19). The effect of ROS on 
T cell activation was independent on the ROS producing capacity of the Mph2 
subsets observed in our studies. 
To unravel this effect we searched for possible mechanisms how Mph-derived 
ROS affects T cell function (Chapter 4). We focused on the signals between 
Mph and T cell that allows for T cell activation. These signals involve the MHC 
class 2 molecules, co-stimulatory molecules and cytokines. By means of DPI we 
investigated the MHC class 2 molecule HLA-DR and the co-stimulatory molecule 
CD86 expression on Mph2, Mph2a, and Mph2c and observed no effect on the 
expression of these markers, indicating that there is no ROS dependency of 
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these specific signals. Therefore we investigated the cytokine production of 
Mph2 subsets. The Mph2 subsets were activated by CD40L in order to mimic 
the CD40-CD40L signal between APC-T cell. When testing directly on the 
three different Mph2 subsets, DPI dose-dependently decreased the IL-10 and 
IL-12p40 production of CD40L-stimulated Mph2 subsets. However, the IL-6 
production was not affected, which is interesting due to its pro-inflammatory 
nature. Interestingly, when stimulated with LPS, DPI suppressed the cytokine 
production in all three Mph2 subsets. In mouse Mph decreased IL-10, IL-6 and 
TNF-α production with DPI has been observed as well (20). Thus the decreased 
T cell proliferation in the presence of DPI could be linked to alterations in 
cytokine production, as clearly shown for IL-10 and IL-12p40 production. 
However, a more detailed analysis of the complete cytokine production profile, 
as well as information on other signaling pathways, will be required to fully 
explain the mechanism of ROS-dependent T cell activation. 
ROS-dependent Treg induction
We observed a high ROS producing capacity in Mph2, but in contrast with 
literature no ROS production upon PMA stimulation was shown in GM-CSF-
differentiated Mph1 (Chapter 3). We hypothesized that if Mph-derived 
ROS prevent T cell mediated immune responses, it could do so by inducing 
regulatory T cells (Tregs). It was already shown that anti-inflammatory Mph 
were capable of inducing potent Tregs, whereas in that setting the same was 
not observed with pro-inflammatory Mph (21). Induction of Tregs in a ROS-
dependent manner could be demonstrated in an in vivo DTH model and an 
expansion in the number of Tregs after increasing the ROS producing capacity 
with dexamethasone. This confirmed that Mph-derived ROS can play a role in 
the induction of Tregs (Chapters 2 and 3). In addition, NOX2-derived ROS was 
shown to be involved in suppression of CD4 positive effector cells by Tregs 
(22). These data indicate diminished pro-inflammatory activities and thus less 
inflammation, showing that ROS affect the immune regulatory capacity. 








Table 2: Genes changed in expression when exposed to hydrogen peroxide with the top 5 most downregulated 
genes and top 5 most upregulated genes. Ratio: CD4+ T cells exposed to 4 hours of hydrogen peroxide / CD4+ 
























Interferon-induced protein with tetratricopeptide repeats 3 
Interleukin  1 receptor antagonist
Interferon-induced protein with tetratricopeptide repeats 1
Interferon-induced protein with tetratricopeptide repeats 2 
Tumor necrosis factor receptor superfamily, member 4
FBJ murine osteosarcoma viral oncogene homolog 
Dual specificity phosphatase 1 
Jun proto-oncogene 
Kruppel-like factor 9
Early T-cell activation antigen p60
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(23), which may include both natural and inducible Tregs. Natural Tregs are 
derived from the thymus, whereas inducible Tregs are derived from naïve T cell 
precursors in the periphery and upregulate FoxP3 expression (24). In grafts their 
number is limited and consequently when acute rejection takes place they will 
not be able to prevent rejection. However, the allograft itself has been shown to 
be able to induce or expand Tregs (25,26). Tregs affect immune cells in different 
ways. For example, they produce IL-10 or express cytotoxic T lymphocyte 
antigen 4 (CTLA4), causing decreased APCs activity, which will diminish the 
activity of effector immune cells and decreases the chance of graft rejection. 
Inhibition of CTLA4 or IL-10 in vivo indeed showed impaired Treg-mediated 
regulation in transplantation (27,28). These data show the importance of the 
presence of Tregs in an allograft. Based on our experiments, we believe that 
there may be a link between ROS and Treg induction in vivo. In Chapter 5 we 
investigated the impact of NOX2-mediated ROS production by recipient cells 
in an experimental model of chronic allograft inflammation. We used the model 
of Lewis-to-DA kidney transplantation. As recipients we used the congenic 
rat strains DA.Ncf1DA/DA and DA.Ncf1E3/E3genotypes, which only differ in their 
phagocytic NOX2-derived ROS-producing capacity. DA rats are more prone 
to develop rheumatoid arthritis compared with other rat strains. A naturally 
occurring polymorphism of Ncf1, component of the NADPH oxidase complex, 
was found to regulate the severity of arthritis in rats (29). This polymorphism 
caused reduced ROS production and promoted the activation of arthritogenic 
T cells. Thus the congenic DA.Ncf1DA/DA rats have a reduced NOX2-mediated 
ROS production compared to the DA.Ncf1E3/E3 rats. Large leukocyte clusters 
were observed in the allograft four weeks after transplantation. In addition, 
signs of ROS production was also demonstrated. The leukocyte clusters showed 
no difference regarding composition of myeloid cells or the number of FoxP3 
positive Treg cells. However, T cell infiltrate was significantly reduced in the 
DA.Ncf1E3/E3 recipients having normal ROS production. As a consequence, this 
means that there are relatively more Tregs in the infiltrate. This could suggests a 
regulatory effect of ROS on T cell infiltration, but no effect on other inflammatory 
cells in the allograft. 
Molecular mechanisms of ROS-mediated effects
NOX2-derived ROS from Mph can be produced intracellular, into the 
phagosome, or extracellular, at the plasma membrane (17). The intracellular 
produced ROS are associated with the killing of pathogens and inflammatory 
signaling, extracellular ROS are considered to be second messengers (17). 
We observed that NOX2-derived ROS from Mph affects T cells by inducing 
Tregs and are able to activate T cells in a ROS-dependent manner (Chapters 
2 and 4). Signaling by ROS depends on the location, time, concentration 
and duration of the ROS being produced, contributing to homeostasis and 
physiological cell activation (30). There are several potential ways how ROS 
could work; 1) ROS could work intracellular in the Mph, thereby interfering 
with the signaling pathways determining the T cell stimulatory capacity, 2) ROS 
could be a molecule delivered at the contact between Mph and T cell causing a 
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local change in the redox state of the cell surface molecules important in T cell 
activation, 3) ROS might end up in the T cells and there actively interfere with T 
cell signal transduction. 
We investigated the effect of ROS on T cells at the level of gene and protein 
expression. Hydrogen peroxide was used as the ROS to conduct these 
experiments. We tried to establish potential mechanisms on how Mph-derived 
ROS could affect T cells by searching for genes and proteins that directly or 
indirectly could have an effect on T cell activation.
Molecular mechanisms of ROS-mediated effects on genetic level
In order to investigate gene expression we performed gene expression 
analysis on CD4+ T cells using microarrays (in collaboration with M Eikmans, 
Department of Immunohematology and Blood Transfusion, Leiden University 
Medical Center, Leiden, The Netherlands). We hypothesized that we would 
find genes involved in transcriptional regulation of T cell activation and 
signaling pathways, including cell surface markers and cytokines, able to 
activate and differentiate the T cells. We studied both unstimulated and αCD3/
αCD28-stimulated T cells. First we examined whether our method was valid 
by comparing genes from unstimulated T cells with αCD3/αCD28-stimulated 
T cells. Increased expression of well-known T cell activation genes including 
ICOS, CD69, IL1B, and NFKB1 was observed, confirming T cell activation by 
αCD3/αCD28 (data not shown). Hydrogen peroxide-induced gene expression 
has already been investigated in among others the human HeLa cell line (31), 
and even though the focus in these studies was on oxidative stress, genes in 
involved in apoptosis, cell cycle regulation, cell-cell communication, signal 
transduction, and transcriptional regulation were differentially regulated upon 
treatment (32).   
In the microarray we investigated the effect of 4 hours incubation with 
hydrogen peroxide on CD4+ T cells and Table 2 summarizes the top 5 
genes that changed in expression compared to the controls. Genes with 








Table 3: Most differently expressed genes when exposed to hydrogen peroxide with top 5 most downregulated 
genes and top 5 most upregulated genes. Ratio: αCD3/αCD28 activated CD4+ T cells exposed to 4 hours of 
























Interferon-induced protein with tetratricopeptide repeats 1
interferon-induced protein with tetratricopeptide repeats 2 
Chemokine (C-C motif) ligand 5
Interferon-induced protein with tetratricopeptide repeats 3 
Tumor necrosis factor receptor superfamily, member 4
Jun proto-oncogene 
Zinc finger, MIZ-type containing 1
FBJ murine osteosarcoma viral oncogene homolog 
Mitogen-activated protein kinase 13
Heme oxygenase (decycling) 1
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IFIT3 which upon transcription, inhibit various cellular and viral processes like 
cell proliferation, cell migration and viral replication (33). Anti-inflammatory 
therapy negatively regulates the transcription of the IFIT genes (33), as we 
observed as well, indicating that ROS signaling affects these genes in an anti-
inflammatory manner. IL1RN encodes the protein IL-1RA which inhibits the 
activity of the pro-inflammatory cytokines IL-1α and IL-1β. TNFRS4 (CD134, 
OX40) encodes a stimulatory receptor on T cells (34). The TNF receptor family 
is vital for regulation of T cell activation, differentiation and survival. Members 
of the TNFR family regulate TCR-independent NF-kB activation. Genes with 
increased expression due to hydrogen peroxide included the genes JUN 
and FOS encoding proteins that dimerize forming the transcription factor 
complex AP-1. DUPS1 (MKP-1) dephosphorylates and inactivates MAPKs and 
can attenuate LPS-induced IL-6, IL-10, and TNF-α expression (35). In addition, 
the gene KLF9 encodes a member of the Krüppel-like family of transcription 
factors and CD69 is a T cell activation marker. The genes which are down- and 
upregulated by ROS indicate an increase of inflammatory events and activation 
of the T cells, and although the downregulation of TNFRS4 is not in agreement 
with this, these data indicate that ROS plays a role in TCR-dependent activation 
of T cells. 
We investigated also whether ROS would change the gene expression 
of αCD3/αCD28-activated T cells when simultaneously exposed to ROS. 
Activated cells could have a changed thiol group formation compared with 
unstimulated cells, therefore the effect of ROS on already activated cells might 
be different. Incubation with hydrogen peroxide showed several genes with 
changed expression (Table 3). We again observed decreased expression of 
IFIT1, IFIT2, IFIT3, and TNFRS4. In addition, expression of CCL5 was reduced. 
CCL5 is a chemoattractant secreted by T cells upon activation. Genes with 
increased expression included JUN and FOS. ZMIZ1 encodes a member of the 
protein inhibitor of activated STAT family of proteins (36). MAPK13 is involved 
in a variety of cellular processes, whereas HMOX1 has antioxidant, anti-
inflammatory, and anti-apoptotic properties. The effect of ROS on the gene 
expression on activated T cells is inconsistent showing genes that indicate 
activation (IFIT genes, JUN, FOS, and MAPK13), but also inhibition (TNFRS4, 
CCL5, ZMIZ1, and HMOX1). These data indicate the complexity regarding the 
effect of ROS on T cells and will therefore need more investigation in order to 
beginning to understand ROS signaling pathways.
Molecular mechanisms of ROS-mediated effects at the protein 
level
As an alternative mechanistic explanation, we investigated the effect of ROS 
at the protein level, since there is evidence for a functional role for cysteine 
modifications in response to redox signals. For example, it has been shown 
that ROS can affect cell surface thiols of the proteins integrin α-4, CD4 receptor 
and the virus envelope protein gp120 (37,38). However, the identity and 
significance of these alterations in the protein thiols are still largely unknown. 
For this purpose proteomics were performed by a newly developed method 
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of Isotope-coded affinity tag (ICAT) labeling put into a mass spectrometry 
(in collaboration with PA van Veelen and GMC Janssen, Department of 
Immunohematology and Blood Transfusion, Leiden University Medical Center, 
Leiden, The Netherlands). In order to test this method and trying to validate 
it with known literature, we used Jurkat T cells and hydrogen peroxide as a 
simplified model for Mph and T cells. 
Proteomics was performed using ICAT labeled Jurkat cells which were incubated 
for a short period of time with hydrogen peroxide. We observed and identified 
several membrane and cytoplasmic proteins that upon hydrogen peroxide 
treatment changed their thiol groups. However, although the technical part of 
the CAT appeared to work fine, interpretation of the data was still difficult. For 
example, the period in which hydrogen peroxide could potentially change thiol 
groups of proteins was limited. In addition, when the cells were rested after 
incubation with hydrogen peroxide they would change back to their original 
state. Therefore, the technique and procedures need to be further optimized 
to identify ROS-sensitive proteins involved in T cell activation. However in the 
future this redox-proteomics will allow for a better understanding on how ROS 
may contribute to signaling. 
Concluding remarks
Anti-inflammatory Mph have a high plasticity. Both in vivo and in vitro different 
types of Mph2 have been observed, all presenting an overlapping phenotype, 
but each having specific characteristics. Classifying Mph2 is difficult, especially 
since no specific markers for human Mph2 have yet been identified, as is the 
case for mouse Mph2. Currently, there are a number of markers being used, but 
these are all based on the distinction between Mph1 and Mph2. The expression 
of these specific Mph2 markers is diverse among different Mph2 subsets. 
Therefore it will be more important to perform functional characterization of 
the different Mph2 subsets. As a consequence molecules involved in these 
diverse functions could ultimately serve as specific markers. 
At present, the full mechanism by which Mph-derived ROS affect T cell 
activation and signaling is unknown. We observed that Mph2 activate T cells in 
a ROS-dependent manner but also that the suppression of activated T cells by 
Mph2 was ROS-dependent. We made a first step in trying to identify proteins 
and genes which are redox-sensitive. We decided to make use of inhibitors 
and focus on the signals between Mph and T cell that involve the activation of 
T cells. We observed that some cytokines were affected by DPI: the IL-12p40 
and IL-10 production were suppressed by DPI, whereas no effect was observed 
with IL-6, suggesting that ROS is specifically involved in the regulation of some 
cytokines that may exert its effect on T cells. Affected cytokine production in 
the absence of ROS was also observed by others (39). These results can be a 
new start point for further research in unraveling the mechanism, but how ROS 
affects T cell activation will need further investigations. In summary, T cells are 
activated by Mph-derived ROS and regulation of the cytokine production by 
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Nederlandse samenvatting
De afgelopen jaren is het inzicht in de biologische rol van zuurstofradicalen 
(‘reactive oxygen species’, ROS) dramatisch veranderd. Over het algemeen werd 
er gedacht dat ROS alleen maar schadelijk waren, maar intussen is duidelijk 
geworden dat ROS ook functioneren als belangrijke fysiologische regulatoren 
van intracellulaire signaaltransductie routes. ROS spelen een rol in antigeen 
presentatie en er is aangetoond dat waterstofperoxide, een belangrijke vorm 
van ROS, T cel activatie kan remmen. Ten slotte is aangetoond dat DA ratten 
met een verminderde ROS productie gevoeliger waren voor artritis, en dat 
ook dit gepaard ging met ene veranderde T cel activatie. De reden voor deze 
verminderde ROS productie kwam door een polymorfisme in het Ncf1 gen. Dit 
Ncf1 gen codeert voor het eiwit p47phox, wat een van de belangrijkste eiwitten 
is van het NADPH oxidase complex (NOX2). Dit NOX2 complex produceert 
de ROS superoxide. Muizen die een functioneel NOX2 eiwit p47phox exclusief 
in hun macrofagen tot expressie konden brengen, waren beschermd tegen 
artritis. ROS afkomstig van macrofagen lijken dus een belangrijke rol te spelen 
en daarom wilden wij dit onderwerp in dit proefschrift verder bestuderen door 
verschillende macrofaag-subsets en het immuunmodulerende potentieel van 
ROS geproduceerd door macrofagen te onderzoeken. 
Hoofdstuk 1 geeft algemene achtergrondinformatie met betrekking 
tot macrofagen. Daarnaast wordt er een overzicht van de verschillende 
soorten macrofagen gegeven. Ook wordt de activatie van macrofagen 
en de rol van macrofagen tijdens inflammatie besproken. Verder wordt er 
achtergrondinformatie over ROS gegeven. Ook wordt het NOX2 complex 
beschreven en de gevolgen van mutaties in dit complex. Ten slotte wordt in 
dit overzicht dieper ingegaan op de potentieel immuunmodulerende rol van 
ROS. 
In Hoofdstuk 2 onderzochten we de ROS-producerende capaciteit van 
humane macrofagen. De anti-inflammatoire macrofagen (gedifferentieerd met 
M-CSF; Mph2) hebben een hoge ROS productie na PMA stimulatie, terwijl 
dendritische cellen (gedifferentieerd met GM-CSF en IL-4) hoegenaamd 
geen ROS produceren. In een ‘mixed lymphocyte reaction’ (MLR) waarin T 
cellen daarnaast geactiveerd werden met anti-CD3/anti-CD28, stimuleerden 
dendritische cellen de T cel proliferatie, terwijl Mph2 de T cel proliferatie juist 
onderdrukten. Deze remming bleek ROS-afhankelijk te zijn, want na toevoeging 
van de NOX2-remmer apocynin werd de remming opgeheven. De macrofagen 
induceerden regulatoire T cellen (CD4+CD25+FoxP3+) nadat CD4+CD25- 
T cellen aan deze cellen waren blootgesteld. Na toevoeging van apocynin 
bleek deze inductie ROS-afhankelijk te zijn. Dit konden we bevestigen met 
Mph2 afkomstig van patiënten met ‘chronic granulomatous disease’ (CGD) die 
een mutatie in NOX2 hebben, waarbij we in afwezigheid van ROS productie 
opnieuw verminderde inductie van regulatoire T cellen en meer T cel activatie 
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observeerden. Verder bestudeerden we de rol van ROS in vivo door de T cel 
activatie te bestuderen in een ratmodel met de ‘delayed-type hypersensitivity’ 
(DTH)-respons als uitleessysteem. Hieruit bleek dat het primen van naïeve Lewis 
ratten met Mph2 van DA ratten met een normale ROS-producerende capaciteit 
leidde tot een sterkere inductie van regulatoire T cel in vergelijking met het 
primen met Mph2 van DA ratten met een lage ROS productie. Bovendien 
was de T cel activatie lager met normaal ROS-producerende Mph2 gezien de 
verminderde DTH-respons in vergelijking met laag ROS-producerende Mph2. 
Deze data tonen aan dat ROS geproduceerd door Mph2 een rol spelen in de 
inductie van regulatoire T cellen.
In Hoofdstuk 3 hebben we onderzocht of medicijnen die het immuunsysteem 
onderdrukken een negatief effect kunnen hebben op de ROS productie 
van macrofagen. Dit zou namelijk een nadelig effect kunnen hebben op 
de mogelijkheid om macrofagen als therapie te gebruiken in combinatie 
met de huidige therapieën. We vergeleken hierbij de pro-inflammatoire 
macrofaag (gedifferentieerd met GM-CSF; Mph1) met de anti-inflammatoire 
Mph2. Terwijl Mph2 een hoge ROS productie hebben na PMA stimulatie, 
vertoonden Mph1 juist een lage ROS-producerende capaciteit. Verschillende 
immuunsuppressiva (cyclosporine, tacrolimus, dexamethason, rapamycine, en 
mycofenolaat mofetil) werden aan de Mph1 en Mph2 toegevoegd. Wanneer 
de medicijnen werden toegevoegd op dag 6 van kweek, het moment dat de 
macrofagen gedifferentieerd zijn, was er geen effect op de ROS-producerende 
capaciteit aantoonbaar. Echter, de medicijnen hadden wel een effect op de 
ROS productie wanneer toegediend tijdens het differentiëren van monocyt-
naar-macrofaag (gedurende de eerste 6 dagen). De medicijnen cyclosporine, 
tacrolimus, dexamethason en mycofenolaat mofetil verhoogden de capaciteit 
van Mph2 om ROS te produceren, terwijl rapamycine een remmend effect 
had. Hoewel de verschillende medicijnen geen effect hadden op de ROS-
producerende capaciteit van Mph1, die om te beginnen al laag was, 
verhoogde dexamethason wel de ROS productie van dendritische cellen. Ook 
zorgde dexamethason voor een toename in de expressie van p47phox op zowel 
mRNA als eiwit niveau. Functioneel versterkte dexamethason behandeling van 
Mph2 de suppressie van de productie van IFN-gamma en IL-4 door T cellen, 
hoewel er geen effect te zien was op de proliferatie van T cellen. Ten slotte 
zorgden dexamethason-injecties in vivo voor toename van ROS productie en 
tot verhoogde inductie van regulatoire T cellen, met name in de DA ratten met 
normaal ROS-producerende capaciteit. Hiermee tonen we een nieuw anti-
inflammatoir mechanisme van dexamethason aan. 
In Hoofdstuk 4 onderzochten we de productie van ROS in verschillende Mph2 
subsets en bestudeerden de rol van ROS geproduceerd door Mph2 op T cel 
activatie. Monocyten kunnen op diverse manieren gedifferentieerd worden tot 
Mph2. Deze Mph2 hebben overeenkomende kenmerken, maar zijn fenotypisch 
en functioneel toch verschillend van elkaar. In dit hoofdstuk hebben wij 
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(Mph2a) en IL-10 (Mph2c). Mph2 en Mph2c lijken veel op elkaar: hoge CD14 
en CD163 expressie, lage DC-SIGN expressie, lage productie van de pro-
inflammatoire cytokines IL-6 en IL-12p40, terwijl Mph2a het tegenovergestelde 
laat zien. Ook functioneel zit er een verschil tussen de drie verschillende 
macrofagen: Mph2a is de meest potente T cel activator, terwijl Mph2c de 
slechtste is. De ROS-producerende capaciteit van Mph2 is het hoogst, Mph2c 
heeft een gemiddelde ROS producerende capaciteit, terwijl Mph2a nauwelijks 
in staat zijn om ROS te produceren. Om te onderzoeken of er een omgekeerde 
correlatie was tussen de ROS-producerende capaciteit en de T cel stimulatoire 
capaciteit, hebben we gebruik gemaakt van de NOX2-remmer DPI. Interessant 
genoeg zagen we dat DPI de T cel proliferatie en IFN-gamma productie remde. 
Verder onderzoek toonde aan dat het effect van DPI in de MLR niet op het 
niveau van de T cel plaats vond, maar juist bij de macrofagen. De interactie 
tussen de macrofaag en T cel, bepalend voor de activatie van de T cel, vindt 
plaats op verschillende niveaus waaronder MHC moleculen, co-stimulatoire 
moleculen en cytokine productie. DPI behandeling van Mph had geen effect 
op de expressie van MHC class 2 molecuul HLA-DR en ook geen effect op het 
co-stimulatoire molecuul CD86. Er was echter wel een remmend effect op de 
productie van de cytokines IL-12p40 en IL-10, maar niet IL-6, wanneer de Mph 
gestimuleerd werden met CD40L. DPI onderdrukte ook de IL-12p40 en IL-10 
productie van Mph2, Mph2a, en Mph2c na LPS stimulatie. Deze remming van 
de cytokine productie door Mph kan bijdragen aan de verminderde capaciteit 
om T cellen te activeren. Dus we zien dat ROS een associatie heeft met de 
cytokine productie, maar meer experimenten zijn nodig om het volledige 
mechanisme te kunnen ontrafelen.
In Hoofdstuk 5 hebben we de consequenties onderzocht van NOX2-
gemedieerde ROS productie in een experimenteel model van 
chronische ontsteking in een transplantaat. Hiervoor hebben we een 
niertransplantatiemodel gebruikt met als donor Lewis ratten en als 
ontvanger DA.Ncf1DA/DA en DA.Ncf1E3/E3 ratten, die alleen verschillen in de 
NOX2-producerence capaciteit van hun fagocyten. We waren hierdoor 
in staat het effect te onderzoeken van ROS op de inflammatoire respons in 
de getransplanteerde nier. Een week na de transplantatie van de nier werd 
de contralaterale nier verwijderd, waarna de ratten op dag 30 werden 
opgeofferd. We zagen dat 4 weken na transplantatie de creatinine en ureum 
waardes verhoogd waren ten opzichte van de normaalwaardes. Ook waren 
de albumine waardes in de urine significant verhoogd. Dit bevestigde dat 
we naar een model keken met een chronisch nierfunctie verlies. Schade in de 
getransplanteerde nier werd inderdaad bevestigd door op weefsel niveau een 
verhoogde mate van aankleuring van de schademarker KIM-1 aan te tonen. 
Daarnaast werd het weefsel gekarakteriseerd door een zeer sterke influx van 
ontstekingscellen, aangetoond met de leukocytenmarker CD45. Voor al deze 
parameters was er geen verschil aantoonbaar tussen de ontvanger stammen 
met een verschillende ROS producerende capaciteit.
Om een beter inzicht te krijgen hebben we ook gekeken naar verschillende 
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typen infiltrerende cellen. Verschillende subsets van myeloide cellen waren 
aantoonbaar (aangetoond met antilichamen tegen OX42, ED1, ED2), 
maar de hoeveelheid aankleuring was niet verschillend. Er was ook geen 
significant verschil in de hoeveelheid regulatoire T cellen (aangetoond met 
een antilichaam tegen FoxP3). Wel was er een significant verschil in de T cel 
aankleuring (R73), waarbij er minder T cellen aanwezig waren in de DA.Ncf1E3/E3
ratten in vergelijking met DA.Ncf1DA/DA ratten. Deze data suggereren een 
onderdrukkend effect van ROS op T cel infiltratie, terwijl er geen effect op de 
andere immuuncellen in het transplantaat werd gezien.
Tenslotte wordt in Hoofdstuk 6 een overzicht gegeven van de studies 
beschreven in dit proefschrift waarin we verschillende facetten hebben 
bestudeerd hoe ROS een rol zouden kunnen spelen in de regulatie van 
een immuunrespons. Daarnaast bespreken we aanvullende gegevens over 
potentiele moleculaire mechanismen waarmee ROS zowel op eiwit- als op gen 
niveau hun effecten zouden kunnen bewerkstelligen. We hebben duidelijk 
aangetoond dat ROS-producerende Mph2 in staat zijn regulatoire T cellen te 
induceren, en identificeerden een ROS-gemedieerd effect op T cel infiltratie 
in een niertransplantatiemodel. Naast het feit dat ROS als boodschapper 
tussen antigeen presenterende celen en T cellen kan fungeren, toonden we 
ook duidelijk aan dat ROS een belangrijke plaats hebben in de functionele 
capaciteiten van verschillende Mph subsets. Naast de bestaande gegevens over 
de belangrijke plaats van ROS in oxidatieve stress en andere pro-inflammatoire 
processen, hebben de huidige studies nieuwe inzichten opgeleverd over de 
‘andere kant’ van ROS en de betrokkenheid bij immuunregulerende processen. 
Het verder ontrafelen van deze complexe, en soms tegenstrijdige processen, 
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Dankwoord
Tijdens mijn sollicitatiegesprek kreeg ik te horen dat ik was uitgekozen om te 
beginnen aan het promotieonderzoek wat beschreven is in dit proefschrift. Nu 
is het zover, mijn proefschrift is af! Dit heb ik niet alleen kunnen volbrengen en 
daarom wil ik graag een aantal mensen bedanken.
Allereerst wil ik Cees en Kyra bedanken. Kyra, jouw directe begeleiding in de 
eerste twee jaar van mijn promotieonderzoek en onze nauwe samenwerking 
heeft mij veel geholpen. Na je vertrek ben je steeds betrokken geweest bij 
het werk en ik wil je bedanken voor je altijd snelle reacties op de vele e-mails 
die zijn langsgekomen. Ook heb ik veel kunnen leren van jouw uitgebreide 
kennis. Cees, jou wil ik hartelijk bedanken voor het overnemen van mijn 
dagelijkse begeleiding in de laatste jaren. Jouw opbouwende kritiek heeft er 
aan bijgedragen dat alles toch tot een goed einde is gekomen.
Sandra en Karin, jullie wil ik bedanken voor de prettige samenwerking in 
de afgelopen jaren. Ik heb ontzettend veel van jullie geleerd! Uiteraard ook 
bedankt voor al jullie hulp met het voor elkaar krijgen van de resultaten.
Daarnaast wil ik Danielle, Ria en Nicole bedanken die mij met raad en soms 
met daad bijstonden. Verder wil ik ook de overige mensen van het nierziekten 
lab (Ethan, Karen, en alle anderen) en de vasculaire nefrologie lab (Eric, Ruben, 
Annemarie, en alle anderen) bedanken voor de hulp en de gezellige tijd op 
het werk.
Ik wil ook mijn kamergenoten Pieter, Hetty, Joe, Juha, Jeetindra en Jason 
bedanken voor alle lol en de vele grappen die plaatsvonden. Hierdoor was 
het altijd weer een verassing wat er die dag zou gebeuren. Ook een speciaal 
bedankje voor mijn ex-kamergenoot Roelof die de lay-out verzorgd heeft van 
dit proefschrift.
Ook was er plezierige samenwerking met de afdeling Immunohematologie 
en Bloedtransfusie van het LUMC met Peter van Veelen, George Janssen en 
Michael Eikmans.
Tenslotte wil ik graag mijn familie bedanken. Suzanne en Deborah, bedankt 
voor alle ontspannende en leuke momenten naast het werk. Pap en mam, dat 
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Curriculum vitae
De schrijver van het proefschrift, Marina Kraaij, werd geboren op 28 december 
1984 te Hillegom. In 2003 behaalde zij het VWO diploma aan het Fioretti college 
te Lisse. In datzelfde jaar begon zij met de studie Biomedische Wetenschappen 
aan de Universiteit Leiden. Tijdens deze studie verrichtte zij een Bachelor 
onderzoeksstage op de afdeling Infectieziekten van het LUMC te Leiden onder 
supervisie van Dr. P.H. Nibbering. Tijdens deze stage deed zij onderzoek 
naar de antimicrobiele en immuunmodulerende activiteiten van genetische 
varianten van humaan lactoferrine. De eerste Master onderzoeksstage tijdens 
deze opleiding verrichtte zij op de afdeling Pathologie van het LUMC te Leiden 
onder supervisie van Dr. N.F. de Miranda. Tijdens deze stage werd onderzoek 
gedaan naar de activatie van hypoxia in darmtumoren. De afsluitende Master 
onderzoeksstage tijdens deze opleiding verrichtte zij op de afdeling Cellular 
Medicine in de Musculoskeletal Research Group van de Newcastle University 
te Newcastle onder supervisie van Prof. Dr. J.M. van Laar. Tijdens deze stage 
werd onderzoek gedaan naar de rol van B-cellen in systemische sclerosis. De 
studie Biomedische Wetenschappen werd afgesloten in 2008. Aansluitend 
hierop begon zij in september 2008 aan een Nierstichting-gefinancierd 
promotieonderzoek getiteld ‘Inducing T cell tolerance via macrophage-
derived radicals: a radical way to prevent transplant rejection’ op de afdeling 
Nierziekten van het LUMC onder de supervisie van Dr. K.A. Gelderman en Prof. 
Dr. C. van Kooten. De resultaten van het promotieonderzoek zijn beschreven 
in dit proefschrift. In 2013 verrichtte zij postdoctoraal onderzoek op de 
afdeling Inwendige Geneeskunde, sectie Immunologie en Transplantatie, 
van het Erasmus MC te Rotterdam waar onderzoek werd gedaan naar de 
rol van monocyten in transplantatie in de onderzoeksgroep van Dr. A.T. 
Rowshani. Vanaf 2014 verricht zij postdoctoraal onderzoek op de afdeling 
Infectieziekten en Immunologie, sectie Moleculaire Afweer, op de faculteit 
Diergeneeskunde van de universiteit Utrecht te Utrecht met als onderwerp 
de immuunmodulerende mechanismes van de kip host defense peptide 
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